The Quest for Cellular Prion Protein Functions in the Aged and Neurodegenerating Brain

Rosalina Gavín 1,2,3,4,*, Laia Lidón 1,2,3,4, Isidre Ferrer 3,4,5,6,7 and José Antonio del Río 1,2,3,4

1 Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Science Park of Barcelona, 08028 Barcelona, Spain; llidon@ibecbarcelona.eu (L.L.); jadelrio@ibecbarcelona.eu (J.A.d.R.)
2 Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain
3 Center for Networked Biomedical Research on Neurodegenerative Diseases (Ciberned), 28031 Barcelona, Spain; isidreferrer@ub.edu
4 Institute of Neuroscience, University of Barcelona, 08028 Barcelona, Spain
5 Department of Pathology and Experimental Therapeutics, University of Barcelona, 08907 Barcelona, Spain
6 Senior Consultant, Bellvitge University Hospital, Hospitalet de Llobregat, 08907 Barcelona, Spain
7 Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, 08908 Barcelona, Spain
* Correspondence: rgavin@ub.edu; Tel.: +34-93-4031185

Received: 23 January 2020; Accepted: 27 February 2020; Published: 2 March 2020

Abstract: Cellular (also termed ‘natural’) prion protein has been extensively studied for many years for its pathogenic role in prionopathies after misfolding. However, neuroprotective properties of the protein have been demonstrated under various scenarios. In this line, the involvement of the cellular prion protein in neurodegenerative diseases other than prionopathies continues to be widely debated by the scientific community. In fact, studies on knock-out mice show a vast range of physiological functions for the protein that can be supported by its ability as a cell surface scaffold protein. In this review, we first summarize the most commonly described roles of cellular prion protein in neuroprotection, including antioxidant and antiapoptotic activities and modulation of glutamate receptors. Second, in light of recently described interaction between cellular prion protein and some amyloid misfolded proteins, we will also discuss the molecular mechanisms potentially involved in protection against neurodegeneration in pathologies such as Alzheimer’s, Parkinson’s, and Huntington’s diseases.

Keywords: prion; Tau; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; neuroprotection

1. Introduction

Pathogenic conformational changes of cellular prion protein (PrPC) generates a β-sheet-enriched isoform called PrPSc or prion (word derived from proteinaceous infectious particle) [1–3], the causal agent of prionopathies [1,2]. PrPC, the natural noninfective protein, is a cell surface glycoprotein linked to the membrane by a glycosylphosphatidylinositol (GPI) anchor, and is mainly located in lipid rafts. The protein is encoded by the Prnp gene and expressed in a wide range of tissues in mammals [4–6]. However, central nervous system (CNS) and lymphoid tissues express higher levels of PrPC, making them the best candidates to generate infectious prions. Prionopathies are a group of fatal neurodegenerative diseases (NDDs) that may present as genetic, infectious, or sporadic disorders. Kuru, Creutzfeldt–Jackob disease (CJD), Gertsmann–Straussler–Scheinker syndrome (GSS), and fatal familial insomnia (FFI) are diseases that occur in humans, while bovine spongiform
encephalopathy (BSE) is found in cows, scrapie in sheep, and chronic wasting disease (CWD) in some members of the family Cervidae [7–9]. After the structural transition of PrPc, PrPsc acquires self-aggregative, spreading (intercellular propagation), and infective (understood as a synonym of contagious) properties [10,11].

In recent years, the scientific community has focused attention on defining the term “prion-like” or “prionoid” to describe other proteins with behavior similar to prions in terms of self-aggregation and spreading properties [10–14]. Proteins implicated in different NDDs, including Huntingtin [15], α-synuclein [16–23], amyloid-β (Aβ) [24–26], and tau [27–31], are currently seen in numerous studies as prion-like proteins. In fact, most of them display amino acid domains in their sequence that determine their specific self-aggregation properties [32,33]. However, the transmission of some of these amyloid proteins between individuals, although unlikely, is currently a relevant topic for discussion [34–36].

More relevantly, two or more of these proteinaceous species might coexist in particular NDDs or experimental models (i.e., [37–45]). Thus, the molecular interaction between them and their putative synergistic effects in affected patients are still under debate (i.e, tau and α-synuclein) [46]. However, the question arises when we try to ascertain natural PrPc functions and their specific roles in NDDs other than prionopathies because not only PrPsc (see above) but also PrPc can coexist with most of these amyloids in experimental NDD models and in brain affected tissue (i.e., [22,47–50]). In this sense, Figure 1A illustrates an example of the relevant colocalization between PrPc (green) and Aβ (red) in the postmortem frontal cortex of an Alzheimer’s disease (AD) patient in contrast to other prion-like proteins such as α-synuclein with little colocalization with Aβ-positive plaques in the same context; normal endogenous expression and function of PrPc may be largely compromised in NDDs [51,52]. In this respect, conflicting studies report neurotoxic roles of PrPc in particular NDDs while others point to a neuroprotective function of the protein in the same disease (i.e., AD), discussed below.

In the present review, far from arguing the pathogenicity of PrPsc or other prion-like proteins, which has already been done in several reviews (see, for instance, [53–56]), we will focus our attention on the neuroprotective role of PrPc and its putative implication in amyloid-associated NDDs.

Figure 1. Confocal images of self-aggregative proteins in AD patients. (A) Double-labeling immunofluorescence of PrPc (clone 3F4 directed against aa 109–112 of prion protein, Merck Millipore) and Aβ (rabbit polyclonal antibody directed against the N-terminus 11-pyro E start point of human beta-amyloid, Novus Biologicals) showing colocalization of PrPc in Aβ deposits. (B) Double-labeling immunofluorescence of α-synuclein (clone 5C2 raised against recombinant alpha-synuclein aa 61–95
Cells 2020, 9, 591

purified from *E. coli* (Labome) and Aβ (Novus). Note the absence of clear colocalization between these two proteins. Scale bar values are displayed in the Merge panels.

2. PrP C and Neuroprotection

Since the generation of the first knock-out (Prnp<sup>0/0</sup>) mice of PrP C in 1992, referred to as Zürich 1 [57], researchers have used different Prnp<sup>0/0</sup> mice in their studies (Zürich 1 [58], Edinburgh [59], and Zürich 3 [60]) to validate/reveal processes sustained by the functions of the protein (see also [61,62]). Moreover, the number of functions is paralleled by the numerous descriptions of PrP C interactions [63–66]. However, some attributed functions are controversial to interpret in biological terms [23,63,67,68]. We refer the reader to a compelling description of PrP C interactions [60,69,70] in order to evaluate the pitfalls associated with the genetic background of the Zürich 1 mice. However, one of the most frequently described functions in different experimental models is the participation of PrP C in neuroprotection. In these processes, the “positive” actions of the protein are linked to: i) particular PrP C activities and ii) PrP C interaction with counterpart actors modulating cell signaling cascades and mechanisms involved in neurotoxicity.

2.1. Antioxidant Activity

Membrane-anchored PrP C presents the ability to bind extracellular Cu<sup>2+</sup> ions at the highly conserved octapeptide repeats (OR) region of the protein near the N-terminus [71–74]. This PrP C–Cu<sup>2+</sup> interaction provides antioxidant properties to the protein as demonstrated by reducing copper-mediated oxidative stress [75]. In fact, Prnp<sup>0/0</sup> mice display higher levels of oxidative stress markers in vivo compared to wild-type animals [76–78]. Moreover, in vitro studies have shown that PrP C overexpression in cultured non-neuronal cells results in decreased susceptibility to oxidative damage and toxicity induced by agents such as copper and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) [79–84]. In fact, PrP C levels are increased in neuroblastoma (N2a) and HeLa cells after overload of extracellular copper [85]. Stress-mediated overexpression of PrP C might modulate superoxide dismutase (SOD) [86] and glutathione reductase (GR) activity [83], increasing antioxidant properties in treated cells.

The antioxidant role of PrP C has also been reported in vivo. In this regard, following ischemic insults, Prnp<sup>0/0</sup> mice display larger affected regions with increased cell death than do wild-type mice [87]. In contrast, endogenous PrP C expression can protect against brain damage after traumatic brain injury in mice [88] and during stroke in rats [89–91]. In parallel, as a consequence of the lesion, Prnp expression is increased under oxidative stress conditions [92], and both increased mRNA and protein have been described in neurons located in the penumbra region in ischemic mice [87]. Lastly, the above-mentioned regulation has also been described in humans under oxidative damage or ischemia [87,93]. Overexpression of PrP C by affected brains should be considered an intrinsic response in an attempt to provide long-term neuroprotection, neurogenesis, or angiogenesis [94].

2.2. Antiapoptotic Activity

PrP C not only acts as an antioxidant protein but also exercises direct control on mitochondrial-associated apoptotic signaling. In this sense, overexpression of PrP C protects primary cultured neurons against Bax-mediated cell death [95]. Function-mapping studies have reported that the OR domain of PrP C is mandatory for antiapoptotic function, since deletion of this domain abolishes the protective function of the protein. Other antiapoptotic proteins such as Bcl-2 require the BH2 domain to interact with Bax protein and regulated permeabilization of the mitochondrial membrane [96]. Although PrP C does not contain BH2 domains and does not directly interact with Bax, it is able to bind with the C-terminal domain of Bcl-2 [97,98]. Moreover, ectopic expression of PrP C and Bcl-2 in Prnp<sup>0/0</sup> cells suppresses apoptosis in serum-free conditions [80,99], suggesting the contribution of PrP C to antiapoptotic activity through caspase-dependent apoptotic pathways in mitochondria.
2.3. Regulation of Calcium Homeostasis and Ionotropic Glutamate Receptors by PrPC

Alterations in calcium metabolism have been extensively studied in acute injuries such as ischemia and in neurodegeneration. Relevantly, PrPC may regulate intracellular Ca\(^{2+}\) homeostasis [100–102]. For example, Krebs et al. showed that endoplasmic reticulum (ER) calcium stores respond to H\(_2\)O\(_2\) in a PrPC-dependent way in neuronal cell cultures [103]. The data presented support the relevance of the OR domain of the protein in this function and the activation of a protective signaling cascade involving Src-like tyrosine kinase Fyn. Activated Fyn may further activate cellular phospholipases to generate inositol triphosphate (IP3), leading to the opening of ER-associated calcium channels [104].

In fact, a neuroprotective function of PrP\(^C\) is also supported by several studies describing increased neuronal susceptibility to glutamate agonists in Prnp\(^{-/-}\) mice (see, for instance, [105–107]). In these studies, AMPA/KA receptor dysfunction, largely responsible for excitotoxicity, is highlighted by the absence of PrP\(^C\). Indeed, recent studies have also reported that PrP\(^C\) binds to and modulates N-methyl-D-aspartate receptor (NMDAR) in cooperation with Cu\(^{2+}\) [108–110]. In addition, there is a susceptibility to stroke in rats with downregulation of Prnp and an increased expression of NR2B, a subunit of NMDAR implicated in excitotoxicity-induced neuronal apoptosis [111]. This suggests a functional regulation of ionotropic glutamate receptors by PrP\(^C\). The reader can find additional information about the mechanisms implicated in neuroprotection of excitotoxicity by PrP\(^C\) in recent reviews [112,113].

2.4. Molecular Partners of PrP\(^C\) for Interaction and Cell Signaling

The ability of PrP\(^C\) to bind a variety of other molecules suggests the existence of different physiological roles, which may be context-specific. In this respect, PrP\(^C\) could be considered a cell surface scaffold protein [70] as a means to explain the role of the protein as key in different signaling systems. However, it will be necessary to determine the biological significance of each interaction and the possibilities of response depending on these contacts. In terms of neuroprotection, PrP\(^C\) transduces signals across the plasma membrane by binding to other plasma membrane molecules such as the laminin receptor and neural cell adhesion molecule. These interactions promote cell survival and neurite outgrowth [114,115]. In this sense, cell survival promoted by PrP\(^C\) can involve the activation of both cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) and the ERK1/2 signaling pathways [116], as well as activation of the phosphatidylinositol-3-kinase/Akt pathway [115]. In addition, Moulliet-Richard and colleagues proposed Fyn kinase as an initiator of the cascade leading to ERK1/2 activation by cross-linking of PrP\(^C\) at the cell membrane with antibodies [117]. These and other results support the idea that dimer formation of PrP\(^C\) is essential to its neuroprotective activity since antibody-mediated PrP\(^C\) dimerization elicits rapid phosphorylation of ERK1/2 in cultured cells [118]. Moreover, in the same in vitro model, PrP\(^C\) dimerization also promotes the recruitment of the cAMP responsive element-binding protein (CREB) transcription factor and the transcription of several genes with key functions in cellular protection and neuronal plasticity [119]. In addition, GSK3\(\beta\), whose inhibition is neuroprotective, is a downstream target of PrP\(^C\) dimerization signaling in serotonergic neuronal cells [120]. However, dimer formation of PrP\(^C\) seems to be necessary but not sufficient for its stress protective activity [121].

Another neuroprotective pathway through PrP\(^C\) binding with stress-inducible protein 1 (STI-1) has been reported by [122]. Moreover, Lopes and colleagues showed the effects on both neuritogenesis and survival in hippocampal neurons triggered by STI-1-PrP\(^C\) interaction. In this regard, the neuritogenesis was found to be dependent only on mitogen-activated protein kinase (MAPK) activity, whereas cAMP-dependent PKA actions mediate neuroprotection [123]. In addition, PrP\(^C\) cooperates with STI-1 to regulate SOD activity, and consequently cell survival [124]. In fact, a recent study demonstrates the neuritogenic potential of recombinant PrP\(^C\) [125] which might trigger intracellular signaling cascades after its homophilic interaction with membrane-anchored PrP\(^C\). Indeed, intracellular endocytosed PrP\(^C\) may interact with proteins involved in classical signaling pathways including the growth factor receptor-bound protein 2 (Grb2), an adaptor protein involved in neuronal survival [63,126].
2.5. Physiological Processing of PrPC and Neuroprotective Metabolites

PrPC can be proteolytically cleaved in the two structurally different regions of the protein at the plasmatic membrane. PrPC has a long, flexible N-terminal tail (residues 23–128) and a C-terminal globular domain that contains three α-helices and two parallel stranded β-sheets [127–129] (Figure 2) (the residue numbering refers to mouse PrP (moPrP)). These two regions follow physiological proteolytic processing by α-cleavage (approximately at aa 110), releasing the PrPN1 fragment (aa 23–110) and yielding the PrPC1 fragment tethered to the plasma membrane [130,131]. In addition, minor cleavage, termed β-cleavage, occurs at residues 90–91, releasing aa 23–89 or PrPN2 and PrPC2 [131] (Figure 3A). A third type of cleavage within the OR is induced by reactive oxygen species in the presence of Cu²⁺ [132]. One study [133] showed neuroprotective activity and anti-β-sheet-mediated corruption activity of PrPN1. In this sense, different studies reinforce this hypothesis [134–136], and neurotoxic consequences of the absence of α- or β-cleavage-derived forms of PrPC have been reported [137,138]. In fact, PrPC homodimerization stimulates its trafficking to the plasma membrane and α-cleavage with the consequent production of PrPN1 and PrPC1 [136].

Figure 2. Schema of the PrPC sequence with its different domains showing the interaction of molecules described in this article. SP: signal peptide 1–22 aa; CC1: charged cluster 1,23–30 aa; OR: octarepeat region 60–91 aa; CC2: charged cluster 2, 95–110 aa; HR: hydrophobic region 112–133 aa; H1-3: α-Helix regions 143–452, 171–191, 199–221; GPIp: GPI anchor-signaling peptide. (Numbering based on the moPrP sequence.)

Figure 3. Schematic representation of PrPC isoforms: (A) Cell surface PrPC and the four metabolites resulting from α- and β-cleavage (PrPN1, PrPC1, PrPN2, PrPC2, respectively). Homodimerization of PrPC enhanced α-cleavage and consequently the production of anti-β activity of PrPN1. (B) Cytosolic PrP (CyPrP) and the two transmembrane isoforms termed NtmPrP and CtmPrP with opposite sequence orientations with respect to the lumen of the endoplasmic reticulum. As the CC1 domain is not involved in the generation of different PrPC isoforms, it has not been included in this figure.
In addition, a great range of ligands binding to the N-terminal domain of PrPC are able to trigger rapid endocytosis of the protein. Ligand-induced internalization of PrPC may protect cells in different ways: through the transport and homeostasis of several ligands, including Cu$^{2+}$ and hemin [75,139], by degradation of misfolded or inactive PrPC molecules [140], and by activating PrPC-mediated intracellular cell signaling after the stimuli [141–143]. In this regard, and under physiological conditions, endocytosis is essential to N-terminal PrPC function, although PrPN1 is able to elicit neuroprotective signals independently of internalization [134].

Alternatively, intracellular processing of PrPC could generate additional cytoplasmic forms. A cytosolic form (CyPrP) can be generated, probably as a result of retrotranslocation from the ER or from poor translocation into the ER [144]. CyPrP is proposed as being responsible for protection against Bax-mediated cell death [145,146]. In addition, PrPC presents two transmembrane isoforms, termed N$^\text{am}$PrP and C$^\text{am}$PrP, with opposite sequence orientations with respect to the lumen of the ER [147]. The single-pass transmembrane isoforms represent 2% of total PrPC inserts [148] (Figure 3B), and to date, no physiological function has been detailed for them. However, several studies have associated overexpression of C$^\text{am}$PrP with neurotoxicity [149,150].

3. Functions of PrPC during Aging and Neurodegeneration

In the healthy brain, there is a relationship between PrPC levels and aging. In fact, protein levels are reduced in older human brains [151]. In this sense, aging is associated with an increase in reactive oxygen species (ROS) which inversely correlates with PrPC levels. Moreover, oxidative stress is an important contributing factor in the pathogenesis of many human NDDs, such as prionopathies, Parkinson’s, Huntington’s, Alzheimer’s, and amyotrophic lateral sclerosis [152–154], which leads us to pose the question of what the role of PrPC is in each of these scenarios. In addition, as mentioned above, there is a specific interaction between the principal proteins implicated in these diseases and PrPC, for instance, tau [46,48], A$\beta$ [155,156], and $\alpha$-synuclein [22,23,157], reinforcing the notion of an active role for PrPC in these pathologies. Table 1 summarizes several studies describing examples of the neuroprotective role of PrPC in a number of neurodegenerative diseases and some nonspecific disorders. Please see text for opposing data.

| Disease                  | Finding                                                                 | Model      | Role of PrPC                                                                 | Key Reference(s) |
|--------------------------|-------------------------------------------------------------------------|------------|----------------------------------------------------------------------------|-----------------|
| Alzheimer’s disease      | Inhibition of BACE1                                                     | In vitro   | Decreases A$\beta$ production                                              | [158,159]       |
|                          | Binding of PrPN1 to A$\beta$                                            | In vitro   | Blocks transformation into ADDLs                                            | [160,161]       |
|                          | Binding to STI1                                                         | In vitro   | Decreases ADDLs toxicity                                                   | [162]           |
|                          | Binding to Zn$^{2+}$                                                    | In vitro   | Decreases A$\beta$ aggregation                                             | [163]           |
|                          | Binding of PrPN1 to ADDLs                                                | In vivo    | Decreases ADDLs toxicity                                                   | [164]           |
|                          | Prevention of cell death by A$\beta$                                    | In vivo    | Decreases caspase-3 and Bax/Bcl2 levels                                    | [165]           |
|                          | Increase in PrPN1 production in brain patients                          | Human samples | Blocks transformation into ADDLs                                        | [160]           |
|                          | Increase in brain regions prone to oxidative stress                      | Human samples | SOD and GR activity regulation                                             | [166]           |
|                          | Increase in initial stages of the disease                                | Human samples | Downregulates tau levels                                                   | [167]           |
3.1. PrPc in Alzheimer’s Disease (AD) and Other Tauopathies

AD patients are characterized by a progressive cognitive decline and behavioral changes due to the dysregulation of two prion-like proteins: (i) Aβ, resulting from the abnormally processed amyloid precursor protein (APP) though greater activity of β-secretase-1 (BACE1), and (ii) tau, a microtubule-associated protein that promotes the polymerization and stabilization of microtubules (MT) under the regulatory control of several kinases and phosphatases [171,172]. As a result, the major histopathological hallmarks of the disease are the presence of senile plaques, enriched in Aβ, and neurofibrillary tangles (NFTs) containing hyperphosphorylated tau (e.g., [173,174]). The widely accepted amyloid cascade hypothesis posits that the generation of Aβ and its extracellular deposition in brain parenchyma triggers a sequence of events leading to tau dysfunction following the “staging” theory of disease progression [175,176]. Although higher toxic potential is actually attributed to Aβ-derived diffusible ligands (ADDLs) and not to insoluble forms of Aβ [177], tau is considered decisive for the progression of neurodegeneration [178], and the spreading of the tau pathology in affected individuals correlates well with memory impairment and dementia symptoms [179]. Other tauopathies, with different target cells (from neurons to astroglia or oligodendroglia) include Pick’s disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease (AGD), among others [180,181]. See also [182,183] for recent classifications of tauopathies.

The tau gene (MAPT) is expressed in six isoforms as a result of mRNA alternative splicing in various combinations, distinguishable by the exclusion or inclusion of a repeat region of exon 10 that generates four microtubule-binding repeats (4R) or three (3R) tau, and both with either no (0N), one (1N), or two (2N) amino-terminal inserts [184]. In adult neurons, 3R and 4R tau isoforms are present to a similar degree, localized mainly in axons, but they are also present in the somatodendritic compartment of neurons underlying NFT formation and in AD. NFTs lead to increased MT instability, impaired axonal transport, and profound deficits in synaptic function. Among others,
GSK3β and Cdk5 are the main kinases implicated in the phosphorylation of some tau epitopes described in AD [185–188]. In fact, several of these phosphorylated tau epitopes have been associated with in vitro cellular response to ADDLs [167,189,190].

In AD, there is a colocalization of PrPc and Aβ-containing senile plaques ([49] and Figure 1A). Moreover, PrPc and ADDLs interact specifically in AD patients’ brains [50,191,192], suggesting an active role for PrPc in the disease. In fact, Aβ oligomers influence PrPc trafficking and inhibit PrPc-endocytosis [193], blocking BACE1 regulation by PrPc [194,195]. In addition, a study by Strittmatter’s laboratory pointed to ADDL–PrPc interaction as being responsible for neurodegeneration through regulation of glutamate receptors [50]. Later, other studies reinforced this hypothesis [196–199]. In the effort to explain the consequences of PrPc–ADDLs in glutamate receptor interaction, some groups have shown a physical connection between PrPc and ionotropic glutamate receptor NMDA [197,200] and metabotropic glutamate receptor 5 (mGluR5) [201] (reviewed in [202]). NMDA receptor activity is modulated by PrPc in a copper-dependent manner. Moreover, Um and colleagues linked the dysregulation of NMDA by ADDLs–PrPc with Fyn activation. In fact, Fyn has also been associated with PrPc [203] which presents direct binding to mGluR5, mGluR1, and NMDA receptors as well as tau [197,204–207], supporting a role for it in dysregulating NMDA- or mGluR5-mediated synaptic function as well as tau hyperphosphorylation induced by Aβ [208]. This was demonstrated by Lesne’s laboratory who showed that soluble Aβ binds to PrPc at neuronal dendritic spines where it forms a complex with Fyn and causes tau hyperphosphorylation [209], which may lead to cell death. Regarding synaptic changes and neuronal physiology, some studies reported different data from those reported by Strittmatter’s lab. Indeed, some authors have observed Aβ-induced depression of synaptic transmission in both wild-type and Prnp0/0 mouse slices [210], and others have found that Prnp0/0 and Prnp+/+ mice were equally susceptible to cognitive impairment after Aβ injection into the lateral ventricle [211]. Moreover, Aguzzi’s group has shown there to be no LTP impairment in APP/PS1 mice lacking Prnp [212]. In summary, although the binding of PrPc and ADDLs seems to be accepted, there are some differences in ascertaining whether this interaction affects only synaptic plasticity or cell death as well.

Below we describe several studies in which PrPc developed a neuroprotective role in AD through its natural function/s. For instance, it has been reported that overexpression of PrPc protects against Aβ-mediated cell death (i.e., caspase-3 activation) in mice via control of the Bax/Bcl-2 ratio and, over time, PrPc expression also prevents cognitive dysfunction [165]. In addition, Younan and colleagues have shown that PrPc inhibits fiber formation by trapping free ADDLs and causing disassembly of preformed Aβ fibrils [213]. The authors point to two charged clusters in the N-terminal domain of PrPc as being responsible for Aβ–PrPc binding: (aa 95–110) and (aa 23–27) [21,155,213]. At this point, it is important to keep in mind that the activity of PrPc is finely regulated by its dimerization and that PrPc homodimers stimulate the production of PrPN1, which in turn can bind to Aβ with high affinity, blocking transformation into soluble and toxic ADDLs [136,160,161,164]. In this sense, there is some evidence that α-cleavage (leading to PrPN1 and PrPC1) is increased in postmortem brains of AD patients, reinforcing this neuroprotective notion [160], and inhibition of PrPN1 production promotes AD progression [214]. The hydrophobic domain of the protein (amino acids 112–133), inside the N-terminal domain, is responsible for homodimer formation [121] and perhaps interferes with ADDL binding. In addition, although PrPc could mediate the toxicity of ADDLs [133,215], homodimerization and cleavage may be a common mechanism in preventing this.

In addition, some authors have recently shown that increased PrPc expression downregulates tau protein [167,216,217]. In this sense, we recently reported increased susceptibility of tau phosphorylation to ADDLs in primary cortical cultures lacking PrPc. Reported results indicate that increased PrPc between Braak I and IV stages renders lower tau and phospho-tau. In contrast, PrPc levels decreased at Braak V–VI stages which also correlates with increased amounts of tau and phospho-tau. Taken together, our observations suggest a protective role for PrPc in early stages of AD which may be extendable to other tauopathies [167]. In fact, tau pathology has been reported in
a wide number of prionopathies such as sporadic CJD (sCJD) [35], GSS [218,219], and FFI [220], which showed lower PrPC levels due to the PrPC-to-pathogenic-prion conversion [221].

Regarding pathological phosphorylation of tau, some studies point to GSK3β kinase activity as a key element in neuroprotection, while GSK3β inhibition has been shown to play a pivotal role in synaptic plasticity and long-term potentiation (LTP) [222]. In this sense, PrPC–STI-1 interaction triggers reduction of GSK3β kinase activity which not only may affect tau phosphorylation but may also induce memory impairment [120]. Importantly, the interaction of STI-1 with PrPC was recently shown to hinder the binding of Aβ oligomers to PrPC, overcoming their toxicity [162].

As indicated by several studies, AD (in a broad sense) is characterized by neuroinflammation and oxidative stress [223]. In this sense, it is notable that levels of PrPC are increased between Braak I and IV stages [167], in contrast to decreased levels in advanced stages of the disease [221,224]. PrPC can reduce ROS by its intrinsic copper buffering roles and by modulating SOD1 and GR (see above). Elevated levels of PrPC have been reported to occur in brain regions prone to oxidative stress in AD, suggesting a possible antioxidant function in the disease [166]. In addition, increased expression of the PrPC in the first stages of AD [225,226] may promote competition between different ligands including Aβ (Figure 4). Along this line, zinc is another cation involved in the generation of ROS in neurons, and PrPC mediates uptake of extracellular zinc into neuronal cells [227]. Furthermore, zinc promotes Aβ aggregation and increases insoluble Aβ and its deposition in plaques in an AD mouse model [228,229]. In addition, synaptic zinc favors the attachment of Aβ to NMDAR, mediating its excitotoxicity [230]. This implies that the reduction in PrPC in the advanced AD brain might result in decreased zinc uptake and, consequently, in an increase in the amount of zinc in the synaptic cleft, which would promote Aβ aggregation and synaptic targeting, thereby accelerating the neurodegenerative process.

PrPC has been shown to influence the processing of APP, lowering Aβ production through inhibition of BACE1, suggesting that PrPC functions are beneficial in AD [158,159]. In fact, protein and mRNA levels of PrPC correlate inversely with BACE-1 activity and Aβ levels [151,158,221,226,231,232]. Therefore, a decrease in PrPC levels at medium-late stages of AD may be a primary contributor to neurodegeneration and cognitive impairment.

---

**Figure 4.** Proposal of a putative scenario for neuroprotective intervention of PrPC in AD: 1. Modulating ROS levels; 2. Inhibiting BACE1 activity; 3. Generating PrPN1; 4. Modulating glutamate receptors (both ionotropic (NMDAR) and metabotropic (mGluR5)); 5. Reducing phospho-tau levels through STI-1 interaction and GSK3β inhibition; 6. Reducing ROS levels through STI-1 interaction and consequent SOD modulation; 7. Executing anti-Bax activity; 8. Increasing Zn²⁺ uptake; and 9. Reducing tau levels. Number 10, in italics, represents the direct intervention of ADDLs in PrPC function, inhibiting its endocytosis and/or homodimerization, and competing with Cu²⁺ binding and homeostasis. TGN: Trans-Golgi Network.
3.2. Neuroprotective Role of PrPC in Huntington’s and Parkinson’s Diseases

Despite the paucity of data supporting this hypothesis, assorted evidence suggests that PrPC is a possible neuroprotective key in other diseases, since ROS and free radicals are important mediators of neurotoxicity in several other NDDs—for instance, HD and PD (see above), to which we will now turn.

Huntington’s disease (HD) is an inherited disorder which causes progressive neurodegeneration and which includes motor, cognitive, and psychiatric manifestations until inevitable death occurs [233]. The disease is caused by a polyglutamine (polyQ) expansion (encoded by a CAG repeat) of Huntingtin (HTT) protein. Mutated HTT gene is responsible for the aggregated polyQ, the main component of the proteinaceous deposits found in patient brains [234]. In fact, the age of onset of clinical manifestations is inversely correlated to the length of the polyQ expansion. HTT is expressed in a broad spectrum of neuronal and non-neuronal tissues [235]. Nevertheless, mutated HTT protein promotes progressive neurodegeneration of specific neuronal types, affecting particularly the caudate-putamen and neocortical regions of HD patient brains [236,237]. However, the mechanism of progressive neural loss has not been fully elucidated [238].

Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the world, and it is characterized by the appearance of postural instability, bradykinesia, and tremor. These symptoms are associated with dopaminergic neurodegeneration of the substantia nigra pars compacta (SNC), which innervates basal ganglia and leads to loss of dopamine levels in the striatum [239,240]. Although cell death mechanisms are still unknown, great attention has been focused on α-synuclein because it is the major constituent of Lewy bodies, a principal hallmark of PD. In fact, the spread of fibrillar α-synuclein pathology from the brainstem to limbic and neocortical structures seems to be the strongest neuropathological correlate of emerging dementia and cognitive impairment in the disease [241].

In this scenario, the increased level of oxidatively modified proteins in PD leads to the impairment of several cellular functions [242,243]. We have already reported the importance of PrPC expression in modulating redox homeostasis [75]. In addition, some other common aspects suggest that PrPC may exert neuroprotective functions in these diseases. We already know the importance of biochemical interactions between PrPC and NMDAR or mGluR5 and their possible contribution in AD (see above). Along this line, dysregulation of glutamate receptors plays a role in both HD and PD (reviewed in [244,245]). The excess of glutamate is associated with NDDs, and it becomes excitotoxic by chronically activating both ionotropic and metabotropic glutamate receptors. As a result, an increase in intracellular Ca$^{2+}$ promotes neuronal injury and cell death [246,247]. So, although changes in PRNP expression in early stages of PD and HD are unknown, we may speculate upon a putatively positive role of PrPC in inhibiting glutamate receptors in both diseases.

So, the mechanism that promotes excitotoxicity in HD is thought to be the increased redistribution of NMDAR to the extra-synaptic compartment. Indeed, NMDARs play a key role in neuronal cell death related to HD. Moreover, it has been demonstrated that mutated HTT protein leads to sensitization of the NMDAR, resulting in an increase in extracellular Ca$^{2+}$ invading neurons and promoting excitotoxicity [245]. Furthermore, degeneration of dopaminergic neurons in SNC induces an increase in the activity of glutamatergic neurons in the subthalamic nucleus (STN) which is believed to contribute to the motor symptoms of PD. Group I mGluRs (mGluR1 and mGluR5) are widely expressed in the basal ganglia, especially at postsynaptic sites [248]. However, mGluR5 expression is higher than mGluR1. So, its role in PD motor deficits has been shown in a variety of preclinical studies [249,250]. In fact, antagonism of this receptor ameliorates motor deficits in animal models of PD [251,252]. In this line of research, a new topic of debate is emerging: the possible intervention of PrPC in inducing cognitive impairment through mGluR5 and NMDAR in synucleinopathies. As reported regarding ADDLs-PrPC interaction, Outeiro’s group has indicated that PrPC acts as a receptor for neurotoxic effects of oligomeric α-synuclein [23], although recent results contradict this [67].

As indicated above, neuroprotective PrPC-cleaved-fragment PrPN1 binds to and antagonizes the toxicity of β-sheet rich oligomers. In this line, Wetzel’s group has reported a complex aggregation
pathway for a polyQ containing the N-terminal 17 amino acids of HTT exon 1. In addition, they show the intermediate structures formed during aggregation of peptides [253]. A previous study showed a protective effect of PrP<sup>C</sup> in HTT pathology by reducing aggregation and associated toxicity in neuronal cells [139]. The authors suggest that PrP<sup>C</sup> protects cells from a reduction in proteasome activity by maintaining levels of ROS, thereby helping to prevent protein aggregation. It would be of interest to learn about the roles of full-length PrP<sup>C</sup> protein and cleaved fragments of the protein in the same model. In contrast, HD is considered a four-repeat tauopathy with tau nuclear rods [254]. In addition, GSK3β inhibitors prevent cellular toxicity caused by HD mutation [255]. Taking all the evidence together, it is tempting to posit that PrP<sup>C</sup> may have alternative roles in the disease through regulation of tau levels and modulation of GSK3β activity.

Despite the lack of research about intervention of PrP<sup>C</sup> in the α-synuclein aggregation process, there has been reported to be an increased tendency toward aggregation after oxidation of γ-synuclein, another member of the family that seeds α-synuclein aggregation [256]. In this context, an indirect role of PrP<sup>C</sup> in this process is plausible. Also, we and others have shown that PrP<sup>C</sup> is involved in the propagation and spreading of protofibrils of α-synuclein, with binding between the two proteins in Prnp-transfected HEK293 cells though residues located in the CC2 domain of PrP<sup>C</sup> [47,157,257]. Surprisingly, these are the same amino acids (95–110) involved in binding with Aβ [213]. Since Prnp expression is not mandatory for α-synuclein transport in the mouse brain [258], it is tempting to consider that role in the update and transport to be a collateral effect on the principal neuroprotective role of PrP<sup>C</sup> in the disease. In this respect, we also must recall that both our group and Aulic et al. [157] indicated that PrP<sup>C</sup> is a receptor for the fibrillar forms of α-synuclein [21,257,259]. However, as it has been reported that PrP<sup>C</sup> does not bind to oligomeric species of α-synuclein [67] in contrast to [23], additional studies are needed to ascertain whether oligomeric α-synuclein also mediates similar effects to ADDLs though PrP<sup>C</sup> interaction.

Finally, unpublished studies by our group indicate a tendency toward decreased levels of PrP<sup>C</sup> protein levels in the frontal cortex (area 8) in advanced PD patients (Braak stages 5 and 6) (Figure 5). These results may signal the importance of the protein in the progression of the pathology, as occurs in AD (see above).

![Figure 5](image.png)

**Figure 5.** Graph representing densitometric study of PrP<sup>C</sup> immunoblot analysis in postmortem frontal cortex (Brodmann area 8) from PD patients at different stages compared to non-neurodegenerative cases (nND). Postmortem brain tissue was obtained from Hospital Clinic Brain Bank, following the Code of Ethics of the World Medical Association and the protocols of the local ethical committee. Each plot represents a quantitative level of PrP<sup>C</sup> standardized with actin level for each case. Data shows a progressive, albeit nonsignificant decline in PrP<sup>C</sup> levels in accordance with advance of the disease. Statistical analysis of the resulting data was performed using Anova (Kruskal–Wallis with Dunn multiparametric test) and Prism 8.0 (GraphPad Software, San Diego, CA, USA).
4. Concluding Remarks

The relationship between PrPc and other amyloids (oligomeric (ADDLs) and fibrillar forms (i.e., α-synuclein)) has been well established, and different roles of PrPc in AD have been described (see above). We argue for the role of PrPc in preventing the detrimental effects of the oligomeric species, especially at early stages of the neurodegenerative processes. In this review, we have focused our attention on analyzing a number of mechanisms through which PrPc may act as a neuroprotective molecule. In fact, we must not lose sight of the progression of the protein and its derivate fragments (PrPN1, for instance) in the evolution of diseases. A correlation of the symptoms with levels of PrPC expression may be an important element in increasing our understanding of the natural functions of the protein. In this review, we have also speculated about other diseases of which we do not have so much data, but regarding which it is nonetheless reasonable to posit that PrPc is expressed in order to slow down disease progression. Despite this, we cannot rule out the possibility that enhanced interaction between PrPc and the other proteins implicated in NDDs may involve blocking these specific interactions, thereby allowing the protein to maintain its natural function.

Funding: This research was supported by grants from the Spanish Ministry of Science, Innovation and Universities MCIU/AEI/FEDER (RTI2018-90665-REDT), the CERCA Programme, and the Commission for Universities and Research of the Department of Innovation, Universities, and Enterprise of the Generalitat de Catalunya (SGR2017-648) to JADR; and CIBERNED (CMED2018-2) to IF and JADR. The project leading to these results also received funding from “la Caixa” Foundation (ID 100010434) under the agreement LCF/PR/HR19/52160007 to JADR. L.L. is supported by a fellowship from the FPU Programme of MCIU.

Acknowledgments: The authors thank Tom Yohannan for editorial advice.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Prusiner, S.B. Prions. Proc. Natl. Acad. Sci. USA 1998, 95, 13363–3383.
2. Prusiner, S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216, 136–144.
3. Bolton, D.C.; McKinley, M.P.; Prusiner, S.B. Identification of a protein that purifies with the scrapie prion. Science 1982, 218, 1309–1311.
4. Ford, M.J.; Burton, L.J.; Morris, R.J.; Hall, S.M. Selective expression of prion protein in peripheral tissues of the adult mouse. Neuroscience 2002, 113, 177–192.
5. Miele, G.; Alejo Blanco, A.R.; Baybutt, H.; Horvat, S.; Manson, J.; Clinton, M. Embryonic activation and developmental expression of the murine prion protein gene. Gene Expr. 2003, 11, 1–12.
6. Nicolas, O.; Gavin, R.; del Rio, J.A. New insights into cellular prion protein (PrPc) functions: The “yin and yang” of a relevant protein. Brain Res. Rev. 2009, 61, 170–184, doi:10.1016/j.brainresrev.2009.06.002.
7. Aguzzi, A.; Sigurdson, C.; Heikenwaelder, M. Molecular mechanisms of prion pathogenesis. Annu. Rev. Pathol. 2008, 3, 11–40, doi:10.1146/annurev.pathmechdis.3.121806.154326.
8. Collinge, J. Prion diseases of humans and animals: Their causes and molecular basis. Annu. Rev. Neurosci. 2001, 24, 519–550.
9. Aguzzi, A.; Baumann, F.; Bremer, J. The prion’s elusive reason for being. Annu. Rev. Neurosci. 2008, 31, 439–477.
10. Aguzzi, A.; Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009, 64, 783–790, doi:10.1016/j.neuron.2009.12.016.
11. Fernandez-Borges, N.; Erana, H.; Elezgarai, S.R.; Harrathi, C.; Gayosso, M.; Castilla, J. Infectivity versus Seeding in Neurodegenerative Diseases Sharing a Prion-Like Mechanism. Int J. Cell Biol. 2013, 2013, 583498, doi:10.1155/2013/583498.
12. Cushman, M.; Johnson, B.S.; King, O.D.; Gitler, A.D.; Shorter, J. Prion-like disorders: Blurring the divide between transmissibility and infectivity. J. Cell Sci. 2010, 123, 1191–1201, doi: 10.1242/jcs.051672.
13. Ayers, J.I.; Cashman, N.R. Prion-like mechanisms in amyotrophic lateral sclerosis. Handb. Clin. Neurol. 2018, 153, 337–354, doi:10.1016/B978-0-444-63945-5.00018-0.
14. Cascarina, S.M.; Ross, E.D. Natural and pathogenic protein sequence variation affecting prion-like domains within and across human proteomes. *BMC Genom.* 2020, 21, 23, doi:10.1186/s12864-019-6425-3.

15. Ren, P.H.; Lauckner, J.E.; Kachirskaia, I.; Heuser, J.E.; Melki, R.; Kopito, R.R. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. *Nat. Cell Biol.* 2009, 11, 219–225, doi:10.1038/ncb1830.ncbi1830.

16. Luk, K.C.; Kehm, V.M.; Zhang, B.; O’Brien, P.; Trojanowski, J.Q.; Lee, V.M. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. *J. Exp. Med.* 2012, 209, 975–986, doi:10.1084/jem.20112457.jem.20112457.

17. Masuda-Suzukake, M.; Nonaka, T.; Hosokawa, M.; Oikawa, T.; Arai, T.; Akiyama, H.; Mann, D.M.; Hasegawa, M. Prion-like spreading of pathological alpha-synuclein in brain. *Brain* 2013, 136, 1128–1138, doi:10.1093/brain/awt037.awt037.

18. Aulic, S.; Le, T.T.; Moda, F.; Abounit, S.; Corvaglia, S.; Casalis, L.; Gustinich, S.; Zurzolo, C.; Tagliavini, F.; Legname, G. Defined alpha-synuclein prion-like molecular assemblies spreading in cell culture. *BMC Neurosci.* 2014, 15, 69, doi:10.1186/1471-2202-15-69.

19. Lee, H.J.; Patel, S.; Lee, S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. *J. Neurosci.* 2005, 25, 6016–6024, doi:10.1523/JNEUROSCI.0692-05.2005.

20. Desplats, P.; Lee, H.J.; Bae, E.J.; Patrick, C.; Rockenstein, E.; Crews, L.; Spencer, B.; Masliah, E.; Lee, S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. *Proc. Natl. Acad. Sci. USA* 2009, 106, 13010–13015, doi:10.1073/pnas.0903691106.

21. Del Rio, J.A.; Ferrer, I.; Gavin, R. Role of cellular prion protein in interneuronal amyloid transmission. *Prog. Neurobiol.* 2018, 165-167, 87-102, doi:10.1016/j.pneurobio.2018.03.001.

22. Urrea, L.; Segura-Feliu, M.; Masuda-Suzukake, M.; Hervera, A.; Pedraz, L.; Garcia-Aznar, J.M.; Vila, M.; Samitier, J.; Torrents, E.; Ferrer, I.; et al. Involvement of Cellular Prion Protein in alpha-Synuclein Transport in Neurons. *Mol. Neurobiol.* 2018, 55, 1847–1860, doi:10.1007/s12035-017-0451-4.

23. Ferreira, D.G.; Temido-Ferreira, M.; Vicente Miranda, H.; Batalha, V.L.; Coelho, J.E.; Szegó, E.M.; Marques-Morgado, I.; Vaz, S.H.; Rhee, J.S.; Schmitz, M.; et al. alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. *Nat. Neurosci.* 2017, 20, 1569–1579, doi:10.1038/nn.4648.

24. Nath, S.; Agholme, L.; Kurudenkandy, F.R.; Granseath, B.; Marcusson, J.; Hallbeck, M. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of beta-amyloid. *J. Neurosci.* 2012, 32, 8767–8777, doi:10.1523/JNEUROSCI.0615-12.

25. Domert, J.; Rao, S.B.; Agholme, L.; Brorsson, A.C.; Marcusson, J.; Hallbeck, M.; Nath, S. Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. *Neurobiol. Dis.* 2014, 65, 82–92, doi:10.1016/j.nbd.2013.12.019.

26. Eisele, Y.S.; Obermuller, U.; Heilbronner, G.; Baumann, F.; Kaeser, S.A.; Woliburg, H.; Walker, L.C.; Staufenbiel, M.; Heikenwalder, M.; Jucker, M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. *Science* 2010, 330, 980–982, doi:10.1126/science.1194516.

27. Clavaguera, F.; Bolmont, T.; Crowther, R.A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A.K.; Beibel, M.; Staufenbiel, M.; et al. Transmission and spreading of tauopathy in transgenic mouse brain. *Nat. Cell Biol.* 2009, 11, 909–913, doi:10.1038/ncb1901.

28. Frost, B.; Ollesch, J.; Wille, H.; Diamond, M.I. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. *J. Biol. Chem.* 2009, 284, 3546–3551, doi:10.1074/jbc.M805627200.

29. Sydow, A.; Mandelkow, E.M. ‘Prion-like’ propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy. *Neurodegener. Dis.* 2010, 7, 28–31, doi:10.1159/000283479.

30. Guo, J.L.; Lee, V.M. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. *J. Biol. Chem.* 2011, 286, 15317–15331, doi:10.1074/jbc.M110.209296.

31. Clavaguera, F.; Akatsu, H.; Fraser, G.; Crowther, R.A.; Frank, S.; Hench, J.; Probst, A.; Winkler, D.T.; Reichwald, J.; Staufenbiel, M.; et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. *Proc. Natl. Acad. Sci. USA* 2013, 110, 9535–9540, doi:10.1073/pnas.1301175110.

32. Michelitsch, M.D.; Weissman, J.S. A census of glutamine/asparagine-rich regions: Implications for their conserved function and the prediction of novel prions. *Proc. Natl. Acad. Sci. USA* 2000, 97, 11910–11915, doi:10.1073/pnas.97.22.11910.

33. Sabate, R.; Rousseau, F.; Schymkowitz, J.; Ventura, S. What makes a protein sequence a prion? *PLoS Comput. Biol.* 2015, 11, e1004013, doi:10.1371/journal.pcbi.1004013.
34. Jaunmuktane, Z.; Mead, S.; Ellis, M.; Wadsworth, J.D.; Nicoll, A.J.; Kenny, J.; Launchbury, F.; Linehan, J.; Richard-Loendt, A.; Walker, A.S.; et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 2015, 525, 247–250, doi:10.1038/nature15369.

35. Frontzek, K.; Lutz, M.I.; Aguzzi, A.; Kovacs, G.G.; Budka, H. Amyloid-beta pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med. Wkly 2016, 146, w14287, doi:10.4141/smw.16.14287.

36. Kovacs, G.G.; Lutz, M.I.; Ricken, G.; Stробел, T.; Hoffberger, R.; Preusser, M.; Regelsberger, G.; Honigshnabl, S.; Reiner, A.; Fischer, P.; et al. Dura mater is a potential source of Abeta acts. Acta Neuropathol. 2016, 131, 911–923, doi:10.1007/s00401-016-1565-x.

37. Hansen, L.A.; Masliah, E.; Terry, R.D.; Mirra, S.S. A neuropathological subset of Alzheimer’s disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol. 1989, 78, 194–201.

38. Race, B.; Phillips, K.; Kraus, A.; Chesebro, B. Phosphorylated human tau associates with mouse prion protein amyloid in scrapie-infected mice but does not increase progression of clinical disease. Prion 2016, 10, 319–330, doi:10.1080/19336896.2016.1199313.

39. Debatin, L.; Streffer, J.; Geissen, M.; Matschke, J.; Aguzzi, A.; Glatzel, M. Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener. Dis. 2008, 5, 347–354, doi:10.1159/000121890.

40. Hainfellner, J.A.; Wanschitz, J.; Jellinger, K.; Liberski, P.P.; Gullotta, F.; Budka, H. Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol. 1998, 96, 116–122.

41. Barcikowska, M.; Kwiecinski, H.; Liberski, P.P.; Kowalski, J.; Brown, P.; Gajdusek, D.C. Creutzfeldt-Jakob disease with Alzheimer-type A beta-reactive amyloid plaques. Histopathology 1995, 26, 445–450.

42. Leuba, G.; Saini, K.; Savioz, A.; Charnay, Y. Early-onset familial Alzheimer disease with coexisting beta-amyloid and prion pathology. JAMA 2000, 283, 1689–1691, doi:10.1001/jama.283.13.1689-a.

43. Alzualde, A.; Indakoeetxea, B.; Ferrer, I.; Moreno, F.; Barandiaran, M.; Gorostidi, A.; Estanga, A.; Ruiz, I.; Calero, M.; van Leeuwen, F.W.; et al. A novel PRNP Y218N mutation in Gerstmann-Strassler-Scheinker disease with neurofibrillary degeneration. J. Neuropathol. Exp. Neurol. 2010, 69, 789–800, doi:10.1097/NEN.0b013e3181e85737.

44. Irwin, D.J.; Lee, V.M.; Trojanowski, J.Q. Parkinson’s disease dementia: Convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat. Rev. Neurosci. 2013, 14, 626–636, doi:10.1038/nrn3549.

45. Cali, I.; Cohen, M.L.; Haik, S.; Parchi, P.; Giacone, G.; Collins, S.J.; Kofsky, D.; Wang, H.; McLean, C.A.; Brandel, J.P.; et al. Iatrogenic Creutzfeldt-Jakob disease with Amyloid-beta pathology: An international study. Acta Neuropathol. Commun. 2018, 6, 5, doi:10.1186/s40478-017-0503-z.

46. Dasari, A.K.R.; Kayed, R.; Wi, S.; Lim, K.H. Tau Interacts with the C-Terminal Region of alpha-Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations. Biochemistry 2019, 58, 2814–2821, doi:10.1021/acs.biochem.9b00215.

47. Han, J.; Zhang, J.; Yao, H.; Wang, X.; Li, F.; Chen, L.; Gao, C.; Gao, J.; Nie, K.; Zhou, W.; et al. Study on interaction between microtubule associated protein tau and prion protein. Sci. China C Life Sci. 2006, 49, 473–479.

48. Wang, X.F.; Dong, C.F.; Zhang, J.; Wan, Y.Z.; Li, F.; Huang, Y.X.; Han, L.; Shan, B.; Gao, C., Han, J.; et al. Human tau protein forms complex with PrP and some GSS- and CJD-related PrP mutants possess stronger binding activities with tau in vitro. Mol. Cell Biochem. 2008, 310, 49–55, doi:10.1007/s11010-007-9664-6.

49. Ferrer, I.; Blanco, R.; Carmona, M.; Puig, B.; Ribera, R.; Rey, M.J.; Ribaltal, T. Prion protein expression in senile plaques in Alzheimer’s disease. Acta Neuropathol. 2001, 101, 49–56.

50. Lauren, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Celluar prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457, 1128–1132, doi:10.1038/nature07761.

51. Meyne, F.; Gloeckner, S.F.; Ciesielczyk, B.; Heinemann, U.; Krasnianski, A.; Meissner, B.; Zerr, I. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J. Alzheimers Dis. 2009, 17, 863–873, doi:10.3233/JAD-2009-1110.

52. Llorens, F.; Villar-Pique, A.; Schmitz, M.; Diaz-Lucena, D.; Wohlhage, M.; Hermann, P.; Goebel, S.; Schmidt, I.; Glatzel, M.; Hauw, J.J.; et al. Plasma total prion protein as a potential biomarker for neurodegenerative dementia: Diagnostic accuracy in the spectrum of prion diseases. Neuropathol. Appl. Neurobiol. 2019, 10.1111/nan.12573, doi:10.1111/nan.12573.
53. Aguzzi, A.; Lakkaraju, A.K. Cell Biology of Prions and Prionoids: A Status Report. *Trends Cell Biol.* 2016, 26, 40–51, doi:10.1016/j.tcb.2015.08.

54. Houston, F.; Andreoletti, O. Animal prion diseases: The risks to human health. *Brain Pathol.* 2019, 29, 248–262, doi:10.1111/bpa.12696.

55. Asher, D.M.; Gregori, L. Human transmissible spongiform encephalopathies: Historic view. *Handb. Clin. Neurol.* 2018, 153, 1–17, doi:10.1016/B978-0-444-63945-5.00001-5.

56. O’Carroll, A.; Coyle, J.; Gambin, Y. Prions and Prion-like assemblies in neurodegeneration and immunity: The emergence of universal mechanisms across health and disease. *Semin. Cell Dev. Biol.* 2019, 101, S10.1016/j.semcdb.2019.01.002, doi:10.1016/j.semcdb.2019.01.012.

57. Bueler, H.; Fischer, M.; Lang, Y.; Bluethmann, H.; Lipp, H.P.; DeArmond, S.J.; Prusiner, S.B.; Aguet, M.; Weissmann, C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. *Nature* 1992, 356, 577–582.

58. Rossi, D.; Cozzio, A.; Flechsig, E.; Klein, M.A.; Rulicke, T.; Aguzzi, A.; Weissmann, C. Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. *EMBO J.* 2001, 20, 694–702.

59. Manson, J.C.; Clarke, A.R.; Hooper, M.L.; Aitchison, L.; McConnell, I.; Hope, J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. *Mol. Neurobiol.* 1994, 8, 121–127.

60. Nuvolone, M.; Hermann, M.; Sorce, S.; Russo, G.; Tiberi, C.; Schwarz, P.; Minikel, E.; Sanoudou, D.; Pelczar, P.; Aguzzi, A. Strictly co-isogenic C57BL/6-Jl-Prnp-/ mice: A rigorous resource for prion science. *J. Exp. Med.* 2016, 213, 313–327, doi:10.1084/jem.20151610.

61. Steele, A.D.; Lindquist, S.; Aguzzi, A. The prion protein knockout mouse: A phenotype under challenge. *Prion* 2007, 1, 83–93.

62. Del Rio, J.A.; Gavin, R. Functions of the cellular prion protein, the end of Moore’s law, and Ockham’s razor theory. *Prion* 2016, 10, 25–40, doi:10.1080/19336896.2015.1126038.

63. Spielhaupter, C.; Schatzl, H.M. PrPC directly interacts with proteins involved in signaling pathways. *J. Biol. Chem.* 2001, 276, 44604–44612.

64. Schmitt-Ulms, G.; Legname, G.; Baldwin, M.A.; Ball, H.L.; Bradon, N.; Bosque, P.J.; Crossin, K.L.; Edelman, G.M.; DeArmond, S.J.; Cohen, F.E.; et al. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. *J. Mol. Biol.* 2001, 314, 1209–1225, doi:10.1006/jmbi.2000.5183.

65. Zafar, S.; von Ahsen, N.; Oellerich, M.; Zerr, I.; Schulz-Schaeffer, W.J.; Armstrong, V.W.; Asif, A.R. Proteomics approach to identify the interacting partners of cellular prion protein and characterization of Rab7a interaction in neuronal cells. *J. Proteome Res.* 2011, 10, 3123–3135, doi:10.1021/pr2001989.

66. Kuffer, A.; Lakkaraju, A.K.; Mogha, A.; Petersen, S.C.; Airich, K.; Doucerain, C.; Marpakwar, R.; Bakir, P.; Senatore, A.; Monnard, A.; et al. The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6. *Nature* 2016, 536, 464–468, doi:10.1038/nature19312.

67. La Vitola, P.; Beeg, M.; Balducci, C.; Santamarina, G.; Restelli, E.; Colombo, L.; Caldinelli, L.; Pollegioni, L.; Gobbi, M.; Chiesa, R.; et al. Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. *Brain* 2019, 142, 249–254, doi:10.1093/brain/awy318.

68. Azzalin, A.; Del Vecchio, I.; Chiarelli, L.R.; Valentini, G.; Comincini, S.; Ferretti, L. Absence of interaction between doppel and GFAP, Grb2, PrPc proteins in human tumor astrocytic cells. *Anticancer Res.* 2005, 25, 4369–4374.

69. Nuvolone, M.; Kana, V.; Hutter, G.; Sakata, D.; Mortin-Toth, S.M.; Russo, G.; Danska, J.S.; Aguzzi, A. SIRPalpha polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells. *J. Exp. Med.* 2013, 210, 2539–2552, doi:10.1084/jem.20131274.

70. Linden, R. The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules. *Front. Mol. Neurosci.* 2017, 10, 77, doi:10.3389/fnmol.2017.00077.

71. Brown, D.R.; Qin, K.; Herms, J.W.; Madlung, A.; Manson, J.; Strome, R.; Fraser, P.E.; Kruck, T.; von Bohlen, A.; Schulz-Schaeffer, W.; et al. The cellular prion protein binds copper in vivo. *Nature* 1997, 390, 684–687.

72. Viles, J.H.; Cohen, F.E.; Prusiner, S.B.; Goodin, D.B.; Wright, P.E.; Dyson, H.J. Copper binding to the prion protein: Structural implications of four identical cooperative binding sites. *Proc. Natl. Acad. Sci. USA* 1999, 96, 2042–2047.

73. Evans, E.G.; Pushie, M.J.; Markham, K.A.; Lee, H.W.; Millhauser, G.L. Interaction between Prion Protein’s Copper-Bound Octarepeat Domain and a Charged C-Terminal Pocket Suggests a Mechanism for N-Terminal Regulation. *Structure* 2016, 24, 1057–1067, doi:10.1016/j.str.2016.04.017.
74. Nguyen, X.T.A.; Tran, T.H.; Cojoc, D.; Legname, G. Copper Binding Regulates Cellular Prion Protein Function. Mol. Neurobiol. 2019, 56, 6121–6133, doi:10.1007/s12035-019-1510-9.
75. Vassallo, N.; Herms, J. Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J. Neurochem. 2003, 86, 538–544, doi:10.1046/j.1471-4159.2003.01882.x.
76. Brown, D.R.; Nicholas, R.S.; Canevari, I. Lack of prion protein expression results in a neuronal phenotype sensitive to stress. J. Neurosci. Res. 2002, 67, 211-224.
77. Wong, B.S.; Liu, T.; Li, R.; Pan, T.; Petersen, R.B.; Smith, M.A.; Gambetti, P.; Perry, G.; Manson, J.C.; Brown, D.R.; et al. Increased levels of oxidative stress stress markers detected in the brains of mice devoid of prion protein. J. Neurosci. 2001, 76, 565–572.
78. Klamt, F.; Dal-Pizzol, F.; Conte da Frota, M.L., Jr.; Walz, R.; Andrades, M.E.; da Silva, E.G.; Brentani, R.R.; Izquierdo, I.; Fonseca Moreira, J.C. Imbalance of antioxidant defense in mice lacking cellular prion protein. Free Radic Biol. Med. 2001, 30, 1137-1144, doi:10.1016/S08915849(01)005123.
79. Brown, D.R.; Schulz-Schaeffer, W.J.; Schmidt, B.; Kretzschmar, H.A. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp. Neurol. 1997, 146, 104–112.
80. Brown, D.R.; Besinger, A. Prion protein expression and superoxide dismutase activity. Biochem. J. 1998, 334 (Pt. 2), 423-429.
81. Kuwahara, C.; Takeuchi, A.M.; Nishimura, T.; Haraguchi, K.; Kubosaki, A.; Matsumoto, Y.; Saeki, K.; Matsumoto, Y.; Yokoyama, T.; Itohara, S.; et al. Prions prevent neuronal cell-line death. Nature 1999, 400, 225–226.
82. Withee, J.L.; Sen, R.; Cyert, M.S. Ion tolerance of Saccharomyces cerevisiae lacking the Ca2+/CaM-dependent phosphatase (calcineurin) is improved by mutations in URE2 or PMA1. Genetics 1998, 149, 865-878.
83. White, A.R.; Collins, S.J.; Maher, F.; Jobling, M.F.; Stewart, L.R.; Thyer, J.M.; Beyreuther, K.; Masters, C.L.; Cappai, R. Prion protein-deficient neurons reveal lower glutathione reductase activity and increased susceptibility to hydrogen peroxide toxicity. Am. J. Pathol. 1999, 155, 1723–1730, doi:10.1016/S0002-9440(10)65487-9.
84. Nishimura, T.; Sakudo, A.; Nakamura, I.; Lee, D.C.; Taniuchi, Y.; Saeki, K.; Matsumoto, Y.; Ogawa, M.; Sakaguchi, S.; Itohara, S.; et al. Cellular prion protein regulates intracellular hydrogen peroxide level and prevents copper-induced apoptosis. Biochem. Biophys. Res. Commun. 2003, 323, 218–222.
85. Qin, K.; Zhao, L.; Ash, R.D.; McDonough, W.F.; Zhao, R.Y. ATM-mediated transcriptional elevation of prion in response to copper-induced oxidative stress. J. Biol. Chem. 2009, 284, 4582-4593, doi:10.1074/jbc.M808410200.
86. Sakudo, A.; Lee, D.C.; Saeki, K.; Nakamura, Y.; Inoue, K.; Matsumoto, Y.; Itohara, S.; Onodera, T. Impairment of superoxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line. Biochem. Biophys. Res. Commun. 2003, 308, 660–667.
87. McMennan, N.F.; Brennan, P.M.; McNeill, A.; Davies, I.; Fotheringham, A.; Rennison, K.A.; Ritchie, D.; Brannan, F.; Head, M.W.; Ironside, J.W.; et al. Prion protein accumulation and neuroprotection in hypoxic brain damage. Am. J. Pathol. 2004, 165, 227–235, doi:10.1016/S0002-9440(10)63291-9.
88. Hoshino, S.; Inoue, K.; Yokoyama, T.; Kobayashi, S.; Asakura, T.; Teramoto, A.; Itohara, S. Prions protect brain damage after experimental brain injury: A preliminary report. Acta Neurochir. Suppl. 2003, 86, 297–299.
89. Shyu, W.C.; Lin, S.Z.; Chiang, M.F.; Ding, D.C.; Li, K.W.; Chen, S.F.; Yang, H.I.; Li, H. Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J. Neurosci. 2005, 25, 8967-8977, doi:10.1523/JNEUROSCI.1115-05.2005.
90. Spudich, A.; Frigg, R.; Kiliar, E.; Kiliar, U.; Oesch, B.; Raeber, A.; Bassetti, C.L.; Hermann, D.M. Aggravation of ischemic brain injury by prion protein deficiency: Role of ERK-1/-2 and STAT-1. Neurobiol. Dis. 2005, 20, 442–449, doi:10.1016/j.nbd.2005.04.002.
91. Weise, J.; Crome, O.; Sandau, R.; Schulz-Schaeffer, W.; Bahr, M.; Zerr, I. Upregulation of cellular prion protein (PrPC) after focal cerebral ischemia and influence of lesion severity. Neurosci. Lett. 2004, 372, 146–150, doi:10.1016/j.neulet.2004.09.030.
92. Williams, W.M.; Stadtman, E.R.; Moskovitz, J. Ageing and exposure to oxidative stress in vivo differentially affect cellular levels of PrP in mouse cerebral microvessels and brain parenchyma. Neuropathol. Appl. Neurobiol. 2004, 30, 161-168, doi:10.1111/j.1365-2990.2003.00523.x.
93. Esiri, M.M.; Carter, J.; Ironside, J.W. Prion protein immunoreactivity in brain samples from an unselected autopsy population: Findings in 200 consecutive cases. *Neuropathol. Appl. Neurobiol.* 2000, 26, 273–284, doi:10.1046/j.1365-2990.2000.00239.x.

94. Doepner, T.R.; Kaltwasser, B.; Schlechter, J.; Jaschke, J.; Kilic, E.; Bahr, M.; Hermann, D.M.; Weise, J. Cellular prion protein promotes post-ischemic neuronal survival, angiogenesis and enhances neural progenitor cell homing via proteasome inhibition. *Cell Death Dis.* 2015, 6, e2024, doi:10.1038/cddis.2015.365.

95. Bouhkar, Y.; Zhang, Y.; Goodyer, C.G.; LeBlanc, A. Prion protein protects human neurons against Bax-mediated apoptosis. *J. Biol. Chem.* 2001, 276, 39145–39149.

96. Yin, X.M.; Olvai, Z.N.; Korsmeyer, S.J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. *Nature* 1994, 369, 321–323, doi:10.1038/369321a0.

97. Kurschner, C.; Morgan, J.I. Analysis of interaction sites in homo- and heteromeric complexes containing Bcl-2 family members and the cellular prion protein. *Brain Res.* 1996, 37, 249–258.

98. Kurschner, C.; Morgan, J.I. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. *Brain Res.* 1995, 30, 165–168, doi:10.1016/0006-8993(95)00314-6.

99. Kim, B.H.; Lee, H.G.; Choi, J.K.; Kim, J.I.; Choi, E.K.; Carp, R.I.; Kim, Y.S. The cellular prion protein (PrPC) prevents apoptotic neuronal cell death and mitochondrial dysfunction induced by serum deprivation. *Brain Res.* 2004, 124, 40–50.

100. Herms, J.W.; Korte, S.; Gall, S.; Schneider, I.; Dunker, S.; Kretzschmar, H.A. Altered intracellular calcium homeostasis in cerebellar granule cells of prion protein-deficient mice. *J. Neurochem.* 2000, 75, 1487–1492.

101. Korte, S.; Vassallo, N.; Kramer, M.L.; Kretzschmar, H.A.; Herms, J. Modulation of L-type voltage-gated calcium channels by recombinant prion protein. *J. Neurochem.* 2003, 87, 1037–1042, doi:10.1046/j.1471-4159.2003.02080.x.

102. Fuhrmann, M.; Bittner, T.; Mitteregger, G.; Haider, N.; Moosmann, S.; Kretzschmar, H.; Herms, J. Loss of the cellular prion protein affects the Ca2+ homeostasis in hippocampal CA1 neurons. *J. Neurochem.* 2006, 98, 1876–1885, doi:10.1111/j.1471-4159.2006.04011.x.

103. Krebs, B.; Wiebelitz, A.; Balitzi-Korte, B.; Vassallo, N.; Paluch, S.; Mitteregger, G.; Onodera, T.; Kretzschmar, H.A.; Herms, J. Cellular prion protein modulates the intracellular calcium response to hydrogen peroxide. *J. Neurochem.* 2007, 100, 358–367, doi:10.1111/j.1471-4159.2006.04256.x.

104. Jayaraman, T.; Ondrias, K.; Ondriasova, E.; Marks, A.R. Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation. *Science* 1996, 272, 1492–1494.

105. Rangel, A.; Burgaya, F.; Gavin, R.; Soriano, E.; Aguzzi, A.; Del Rio, J.A. Enhanced susceptibility of PrP-deficient mice to kainate-induced seizures, neuronal apoptosis, and death: Role of AMPA/kainate receptors. *J. Neurosci.* 2007, 27, 7964–7975, doi:10.1523/JNEUROSCI.2212-07.2007.

106. Carulla, P.; Bribeanu, A.; Rangel, A.; Gavin, R.; Ferrer, I.; Caelles, C.; Del Rio, J.A.; Llorens, F. Neuroprotective role of PrPC against kainate-induced epileptic seizures and cell death depends on the modulation of JNK3 activation by GluR6/7-PSD-95 binding. *Mot. Biol. Cell* 2011, 22, 3041–3054, doi:10.1091/mbc.E11-04-0321.

107. Carulla, P.; Llorens, F.; Matamoros-Angles, A.; Aguilar-Calvo, P.; Espinosa, J.C.; Gavin, R.; Ferrer, I.; Legname, G.; Torres, J.M.; del Rio, J.A. Involvement of PrP(C) in kainate-induced excitotoxicity in several mouse strains. *Sci. Rep.* 2015, 5, 11971, doi:10.1038/srep11971.

108. Gasperini, L.; Meneghetti, E.; Pastore, B.; Benetti, F.; Legname, G. Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. *Antioxid Redox Signal.* 2015, 22, 772–784, doi:10.1089/ars.2014.6032.

109. Khosravani, H.; Zhang, Y.; Tsutsui, S.; Hameed, S.; Altier, C.; Hamid, J.; Chen, L.; Villemaire, M.; Ali, Z.; Jirik, F.R.; et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. *J. Cell Biol.* 2008, 181, 551–565, doi:10.1083/jcb.200711002.

110. Styra, P.K.; You, H.; Zamponi, G.W. Copper-dependent regulation of NMDA receptors by cellular prion protein: Implications for neurodegenerative disorders. *J. Physiol.* 2012, 590, 1357–1368, doi:10.1113/jphysiol.2011.225276.

111. Pham, N.; Dhar, A.; Khalaj, S.; Desai, K.; Taghibiglou, C. Down regulation of brain cellular prion protein in an animal model of insulin resistance: Possible implication in increased prevalence of stroke in prediabetics/diabetics. *Biochim. Biophys. Res. Commun.* 2014, 448, 151–156, doi:10.1016/j.bbrc.2014.04.071.

112. Llorens, F.; Del Rio, J.A. Unraveling the neuroprotective mechanisms of PrP (C) in excitotoxicity. *Prion* 2012, 6, 245–251, doi:10.4161/pri.19639.
113. Black, S.A.; Stys, P.K.; Zamponi, G.W.; Tsutsui, S. Cellular prion protein and NMDA receptor modulation: Protecting against excitotoxicity. *Front. Cell Dev. Biol.* 2014, 2, 45, doi:10.3389/fcell.2014.00045.

114. Graner, E.; Mercadante, A.F.; Zanata, S.M.; Forlenza, O.V.; Cabral, A.L.; Veiga, S.S.; Juliano, M.A.; Roesler, R.; Walz, R.; Minetti, A.; et al. Cellular prion protein binds laminin and mediates neuritogenesis. *Brain Res.* 2000, 76, 85–92.

115. Chen, S.; Mange, A.; Dong, L.; Lehmann, S.; Schachner, M. Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. *Mol. Cell. Neurosci.* 2003, 22, 227–233.

116. Chiariini, L.B.; Freitas, A.R.; Zanata, S.M.; Brentani, R.R.; Martins, V.R.; Lindem, R. Cellular prion protein transduces neuroprotective signals. *EMBO J.* 2002, 21, 3317–3326, doi:10.1093/emboj/cdf324.

117. Mouillet-Richard, S.; Ermonval, M.; Chebassier, C.; Laplanche, J.L.; Lehmann, S.; Launay, J.M.; Kellermann, O. Signal transduction through prion protein. *Science* 2000, 289, 1925–1928.

118. Schneider, B.; Mutel, V.; Pietri, M.; Ermonval, M.; Mouillet-Richard, S.; Kellermann, O. NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells. *Proc. Natl. Acad. Sci. USA* 2003, 100, 13326–13331, doi:10.1073/pnas.2235648100.

119. Pradines, E.; Loubet, D.; Schneider, B.; Launay, J.M.; Kellermann, O.; Mouillet-Richard, S. CREB-dependent gene regulation by prion protein: Impact on MMP-9 and beta-dystroglycan. *Cell Signal.* 2008, 20, 2050–2058, doi:10.1016/j.cellsig.2008.07.016.

120. Hernandez-Rapp, J.; Martin-Lanneree, S.; Hirsch, T.Z.; Pradines, E.; Alleaume-Butaux, A.; Schneider, B.; Baudry, A.; Launay, J.M.; Mouillet-Richard, S. A PrP(C)-caveolin-Lyn complex negatively controls neuronal GSK3beta and serotonin 1B receptor. *Sci. Rep.* 2014, 4, 4881, doi:10.1038/srep04881.

121. Rambold, A.S.; Muller, V.; Ron, U.; Ben-Tal, N.; Winklhofer, K.F.; Tatzelt, J. Stress-protective signalling of prion protein is corrupted by scrapie prions. *EMBO J.* 2008, 27, 1974–1984.

122. Zanata, S.M.; Lopes, M.H.; Mercadante, A.F.; Haji, G.N.; Chiariini, L.B.; Nomizo, R.; Freitas, A.R.; Cabral, A.L.; Lee, K.S.; Juliano, M.A.; et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. *EMBO J.* 2002, 21, 3307–3316, doi:10.1093/emboj/cdf325.

123. Lopes, M.H.; Haji, G.N.; Muras, A.G.; Mancini, G.L.; Castro, R.M.; Ribeiro, K.C.; Brentani, R.R.; Lindem, R.; Martins, V.R. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. *J. Neurosci.* 2005, 25, 11330–11339, doi:10.1523/JNEUROSCI.2313-05.2005.

124. Sakudo, A.; Lee, D.C.; Li, S.; Nakamura, T.; Matsumoto, Y.; Saeki, K.; Itohara, S.; Ikuta, K.; Onodera, T. PrP cooperates with ST11 to regulate SOD activity in PrP-deficient neuronal cell line. *Biochem. Biophys. Res. Commun.* 2005, 328, 14–19.

125. Amin, L.; Nguyen, X.T.; Rolle, I.G.; D’Este, E.; Giachin, G.; Tran, T.H.; Serbec, V.C.; Cojoc, D.; Legname, G. Characterization of prion protein function by focal neurite stimulation. *J. Cell Sci.* 2016, 129, 3878–3891, doi:10.1242/jcs.183137.

126. Lyse, D.A.; Wuthrich, K. Prion protein interaction with the C-terminal SH3 domain of Grb2 studied using NMR and optical spectroscopy. *Biochemistry* 2004, 43, 10393–10399, doi:10.1021/bi494828.

127. Donne, D.G.; Viles, J.H.; Groth, D.; Mehlhorn, I.; James, T.L.; Cohen, F.E.; Prusiner, S.B.; Wright, P.E.; Dyson, H.J. Structure of the recombinant full-length hamster prion protein PrP(29-231): The N terminus is highly flexible. *Proc. Natl. Acad. Sci. USA* 1997, 94, 13452–13457.

128. Riek, R.; Horemann, S.; Wider, G.; Glockshuber, R.; Wuthrich, K. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). *Fecs Lett.* 1997, 413, 282–288.

129. Riek, R.; Horemann, S.; Wider, G.; Billeter, M.; Glockshuber, R.; Wuthrich, K. NMR structure of the mouse prion protein domain PrP(121-321). *Nature* 1996, 382, 180–182.

130. Chen, S.G.; Teplow, D.B.; Parchi, P.; Teller, J.K.; Gambetti, P.; Autilio-Gambetti, L. Truncated forms of the human prion protein in normal brain and in prion diseases. *J. Biol. Chem.* 1995, 270, 19173–19180.

131. Mange, A.; Beranger, F.; Peoc’h, K.; Onodera, T.; Frobert, Y.; Lehmann, S. Alpha- and beta-cleavages of the amino-terminus of the cellular prion protein. *Biol. Cell* 2004, 96, 125–132, doi:10.1016/j.biolcel.2003.11.007.

132. McMahon, H.E.; Mange, A.; Nishida, N.; Creminon, C.; Casanova, D.; Lehmann, S. Cleavage of the amino terminus of the prion protein by reactive oxygen species. *J. Biol. Chem.* 2001, 276, 2286–2291, doi:10.1074/jbc.M007243200.

133. Resenberger, U.K.; Harmeier, A.; Woerner, A.C.; Goodman, J.L.; Muller, V.; Krishnan, R.; Vabulas, R.M.; Kretzschmar, H.A.; Lindquist, S.; Hartl, F.U.; et al. The cellular prion protein mediates neurotoxic signalling
of beta-sheet-rich conformers independent of prion replication. EMBO J. 2011, 30, 2057–2070, doi:10.1038/embj.2011.86.

134. Guillot-Sestier, M.V.; Sunyach, C.; Druon, C.; Scarzello, S.; Checler, F. The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J. Biol. Chem. 2009, 284, 35973–35986, doi:10.1074/jbc.M109.051086.

135. Resenberger, U.K.; Winklhofer, K.F.; Tatzelt, J. Neuroprotective and neurotoxic signaling by the prion protein. Top. Curr. Chem. 2011, 305, 101–119, doi:10.1007/128_2011_160.

136. Beland, M.; Motard, J.; Barbarin, A.; Roucou, X. PrP(C) homodimerization stimulates the production of PrPC cleaved fragments PrPNI and PrPCL. J. Neurosci. 2012, 32, 13255–13263, doi:10.1523/JNEUROSCI.2236-12.2012.

137. McDonald, A.J.; Millhauser, G.L. PrP overdrive: Does inhibition of alpha-cleavage contribute to PrP(C) toxicity and prion disease? Prion 2014, 8, doi:10.4161/prion.28796.

138. Mitteregger, G.; Vosko, M.; Krebs, B.; Xiang, W.; Kohlmansperger, V.; Nolting, S.; Hamann, G.F.; Kretzschmar, H.A. The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol. 2007, 17, 174–183, doi:10.1111/j.1750-3639.2007.00061.x.

139. Lee, K.J.; Panzera, A.; Rogawski, D.; Greene, L. E.; Eisenberg, E. Cellular prion protein protects (PrP(C)) neuronal cells from the effect of huntingtin aggregation. J. Cell Sci. 2007, 120, 2663–2671; doi:10.1242/jcs.04598.

140. Kiachopoulos, S.; Heske, J.; Tatzelt, J.; Winklhofer, K.F. Misfolding of the prion protein at the plasma membrane induces endocytosis, intracellular retention and degradation. Traffic 2004, 5, 426–436, doi:10.1111/j.1398-9219.2004.00185.x.

141. Prado, M.A.; Alves-Silva, J.; Magalhaes, A.C.; Prado, V.F.; Linden, R.; Martins, V.R.; Brentani, R.R. PrP on the road: Trafficking of the cellular prion protein. J. Neurochem. 2004, 88, 769–781, doi:10.1046/j.1471-4159.2003.02199.x.

142. Americo, T.A.; Chiarini, L.B.; Linden, R. Signaling induced by hop/STI-1 depends on endocytosis. Biochem. Biophys. Res. Commun. 2007, 358, 620–625, doi:10.1016/j.bbrc.2007.04.202.

143. Caetano, F.A.; Lopes, M.H.; Hajj, G.N.; Machado, C.F.; Pinto Arantes, C.; Magalhaes, A.C.; Vieira Mde, P.; Americo, T.A.; Massensini, A.R.; Priola, S.A.; et al. Endocytosis of prion protein is required for ERK1/2 signaling induced by stress-inducible protein 1. J. Neurosci. 2008, 28, 6691–6702, doi:10.1523/JNEUROSCI.1701-08.2008.

144. Mironov, A., Jr.; Latawiec, D.; Wille, H.; Bouzamondo-Bernstein, E.; Legname, G.; Williamson, R.A.; Burton, D.; DeArmond, S.J.; Prusiner, S.B.; Peters, P.J. Cytosolic prion protein in neurons. J. Neurosci. 2003, 23, 7183–7193.

145. Roucou, X.; Guo, Q.; Zhang, Y.; Goodyer, C.G.; LeBlanc, A.C. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J. Biol. Chem. 2003, 278, 40877–40881, doi:10.1074/jbc.M306177200.

146. Lin, D.T.; Jodoin, J.; Baril, M.; Goodyer, C.G.; Leblanc, A.C. Cytosolic prion protein is the predominant anti-Bax prion protein form: Exclusion of transmembrane and secreted prion protein forms in the anti-Bax function. Biochim. Et Biophys. Acta 2008, 1783, 2001–2012, doi:10.1016/j.bbapap.2008.05.022.

147. Hegde, R.S.; Mastronardi, J.A.; Scott, M.R.; DeFea, K.A.; Tremblay, P.; Torchia, M.; DeArmond, S.J.; Prusiner, S.B.; Lingappa, V.R. A transmembrane form of the prion protein in neurodegenerative disease. Science 1998, 279, 827–834.

148. Rane, N.S.; Chakrabarti, O.; Feigenbaum, L.; Hegde, R.S. Signal sequence insufficiency contributes to neurodegeneration caused by transmembrane prion protein. J. Cell Biol. 2010, 188, 515–526, doi:10.1083/jcb.200911115.

149. Stewart, R.S.; Piccardo, P.; Ghetti, B.; Harris, D.A. Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein. J. Neurosci. 2005, 25, 3469–3477, doi:10.1523/JNEUROSCI.0105-05.2005.

150. Chakrabarti, O.; Ashok, A.; Hegde, R.S. Prion protein biosynthesis and its emerging role in neurodegeneration. Trends Biochem. Sci. 2009, 34, 287–295, doi:10.1016/j.tibs.2009.03.001.

151. Whitehouse, I.J.; Jackson, C.; Turner, A.J.; Hooper, N.M. Prion protein is reduced in aging and in sporadic but not in familial Alzheimer’s disease. J. Alzheimers Dis. 2010, 22, 1023–1031, doi:10.3233/JAD-2010-101071.

152. Beal, M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38, 357–366, doi:10.1002/ana.410380304.
153. Smith, M.A.; Rottkamp, C.A.; Nunomura, A.; Raina, A.K.; Perry, G. Oxidative stress in Alzheimer’s disease. *Biochim. Et Biophys. Acta* 2000, 1502, 139–144, doi:S0925-4439(00)00040-5.

154. Wong, B.S.; Pan, T.; Liu, T.; Li, R.; Petersen, R.B.; Jones, I.M.; Gambetti, P.; Brown, D.R.; Sy, M.S. Prion disease: A loss of antioxidant function? *Biochem. Biophys. Res. Commun.* 2000, 275, 249–252, doi:10.1006/bbrc.2000.3158.

155. Chen, S.; Yadav, S.P.; Surewicz, W.K. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: Role of N-terminal residues. *J. Biol. Chem.* 2010, 285, 26377–26383, doi:10.1074/jbc.M110.145516.

156. Nieznanski, K.; Surewicz, K.; Chen, S.; Nieznanska, H.; Surewicz, W.K. Interaction between prion protein and Abeta amyloid fibrils revisited. *Acs Chem. Neurosci.* 2014, 5, 340–345, doi:10.1021/cn500019c.

157. Aulic, S.; Masperone, L.; Narkiewicz, J.; Isopi, E.; Bistaffa, E.; Ambrosetti, E.; Pastore, B.; De Cocco, E.; Scaini, D.; Zago, P.; et al. alpha-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate Cell-to-Cell Spreading and Block Prion Replication. *Sci. Rep.* 2017, 7, 10050, doi:10.1038/s41598-017-10236-x.

158. Parkin, E.T.; Watt, N.T.; Hussain, I.; Eckman, E.A.; Eckman, C.B.; Manson, J.C.; Baybutt, H.N.; Turner, A.J.; Hooper, N.M. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer’s amyloid precursor protein. *Proc. Natl. Acad. Sci. USA* 2007, 104, 11062–11067, doi:10.1073/pnas.0609621104.

159. Griffiths, H.H.; Whitehouse, I.J.; Baybutt, H.; Brown, D.; Kellett, K.A.; Jackson, C.D.; Turner, A.J.; Piccardo, P.; Manson, J.C.; Hooper, N.M. Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. *J. Biol. Chem.* 2011, 286, 33489–33500, doi:10.1074/jbc.M111.278556.

160. Beland, M.; Bedard, M.; Tremblay, G.; Lavigne, P.; Roucou, X. Abeta induces its own prion protein N-terminal fragment (PrP(N1))-mediated neutralization in amorphous aggregates. *Neurobiol. Aging* 2014, 35, 1537–1548, doi:10.1016/j.neurobiolaging.2014.02.001.

161. Nieznanski, K.; Choi, J.K.; Chen, S.; Surewicz, K.; Surewicz, W.K. Soluble prion protein inhibits amyloid-beta (Abeta) fibrillization and toxicity. *J. Biol. Chem.* 2012, 287, 33104–33108, doi:10.1074/jbc.C112.400614.

162. Ostapchenko, V.G.; Beraldo, F.H.; Mohammad, A.H.; Xie, Y.F.; Hirata, P.H.; Magalhaes, A.C.; Lamour, G.; Li, H.; Maciejewski, A.; Belrose, J.C.; et al. The prion protein ligand, stress-inducible phosphoprotein 1, regulates amyloid-beta oligomer toxicity. *J. Neurosci.* 2013, 33, 16552–16564, doi:10.1523/JNEUROSCI.3214-13.2013.

163. Watt, N.T.; Griffiths, H.H.; Hooper, N.M. Lipid rafts: Linking prion protein to zinc transport and amyloid-beta toxicity in Alzheimer’s disease. *Front. Cell Dev. Biol.* 2014, 2, 41, doi:10.3389/fcell.2014.00041.

164. Fluharty, B.R.; Biasini, E.; Stravalaci, M.; Sclip, A.; Diomedes, L.; Balducci, C.; La Vitola, P.; Messa, M.; Colombo, L.; Forloni, G.; et al. An N-terminal fragment of the prion protein binds to amyloid-beta oligomers and inhibits their neurotoxicity in vivo. *J. Biol. Chem.* 2013, 288, 7857–7866, doi:10.1074/jbc.M112.423954.

165. Rial, D.; Piernarttici, T.C.; Duarte, F.S.; Tasca, C.I.; Walz, R.; Prediger, R.D. Overexpression of cellular prion protein (PrP(C)) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-beta (Abeta1-42) administration in mice. *Neuroscience* 2012, 215, 79–89, doi:10.1016/j.neuroscience.2012.04.034.

166. Voigtlander, T.; Kloppe, S.; Birner, P.; Jarius, C.; Flicker, H.; Verghese-Nikolakaki, S.; Sklaviadis, T.; Guentaev, M.; Budka, H. Marked increased of neuronal prion protein immunoreactivity in Alzheimer’s disease and human prion diseases. *Acta Neuropathol.* 2001, 101, 417–423.

167. Vergara, C.; Ordonez-Gutierrez, L.; Wandosell, F.; Ferrer, I.; del Rio, J.A.; Gavin, R. Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer’s Disease Evolution. *Mol. Neurobiol.* 2015, 51, 1206–1220, doi:10.1007/s12035-014-8793-7.

168. Steinacker, P.; Hawlik, A.; Lehnhart, S.; Jahn, O.; Meier, S.; Gzeit, E.; Braunstein, K.E.; Krzovska, M.; Schwabenstocker, B.; Jesse, S.; et al. Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis. *Am. J. Pathol.* 2010, 176, 1409–1420, doi:10.2353/ajpath.2010.090355.

169. Huang, S.; Chen, L.; Bladen, C.; Stys, P.K.; Zamponi, G.W. Differential modulation of NMDA and AMPA receptors by cellular prion protein and copper ions. *Mol. Brain* 2018, 11, 62, doi:10.1186/s13041-018-0406-3.

170. Beraldo, F.H.; Arantes, C.P.; Santos, T.G.; Queiroz, N.G.; Young, K.; Rylett, R.J.; Markus, R.P.; Prado, M.A.; Martins, V.R. Role of alpha7 nicotinic acetylcholine receptor in calcium signaling induced by prion protein interaction with stress-inducible protein 1. *J. Biol. Chem.* 2010, 285, 36542–36550, doi:10.1074/jbc.M110.157263.
Plattner, F.; Angelo, M.; Giese, K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 2006, 281, 25457–25465, doi:10.1074/jbc.M603469200.

Vassar, R.; Bennett, B.D.; Babu-Khan, S.; Kahn, S.; Mendiz, E.A.; Denis, P.; Teplow, D.B.; Ross, S.; Amarante, P.; Loeloff, R.; et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735–741, doi:10.1126/science.286.5440.735.

Avila, J. Tau aggregation into fibrillar polymers: Taupathies. FEMS Lett. 2000, 476, 89–92.

Braak, H.; Braak, E. Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol. Scand. Suppl. 1996, 165, 3–12.

Hardy, J.A.; Higgins, G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992, 256, 184–185.

Hardy, J. The relationship between amyloid and tau. J. Mol. Neurosci. 2003, 20, 203–206, doi:10.1385/JMN:20:2:203.

Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trometer, B.; Viola, K.L.; et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95, 6446–6453.

Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect Med. 2011, 1, a006189, doi:10.1101/cshperspect.a006189a.

Braak, H.; Braak, E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239–259.

Buee, L.; Delacourte, A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol. 1999, 9, 681–693.

Umeda, Y.; Taniguchi, S.; Arima, K.; Piao, Y.S.; Takahashi, H.; Iwatsubo, T.; Mann, D.; Hasegawa, M. Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies. Neurosci. Lett. 2004, 359, 151–154, doi:10.1016/j.neulet.2004.01.060.

Hoglinger, G.U.; Respondek, G.; Kovacs, G.G. New classification of tauopathies. Rev. Neurol. (Paris) 2018, 174, 664–668, doi:10.1016/j.neurol.2018.07.001.

Kovacs, G.G. Tauopathies. Handb Clin. Neurol. 2017, 145, 355–368, doi:10.1016/B978-0-12-802395-2.00025-0.

Goedert, M.; Spillantini, M.G.; Jakes, R.; Rutherford, D.; Crowther, R.A. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 1989, 3, 519–526, doi:0896-6273(89)90210-9.

Burack, M.A.; Halpain, S. Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons. Neuroscience 1996, 72, 167–184.

Cruz, J.C.; Tsai, L.H. Cdk5 deregulation in the pathogenesis of Alzheimer’s disease. Trends Mol. Med. 2004, 10, 452–458, doi:10.1016/j.molmed.2004.07.001.

Hooper, C.; Killrick, R.; Lovestone, S. The GSK3 hypothesis of Alzheimer’s disease. J. Neurochem. 2008, 104, 1433–1439, doi:10.1111/j.1471-4159.2007.05194.x.

Ferrer, I.; Gomez-Isla, T.; Puig, B.; Freixes, M.; Ribe, E.; Dalfo, E.; Avila, J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Curr. Alzheimer Res. 2005, 2, 3–18, doi:10.2174/1567205052772713.

Bulbarelli, A.; Lonati, E.; Cazzaniga, E.; Gregori, M.; Masserini, M. Pin1 affects Tau phosphorylation in response to Abeta oligomers. Mol. Cell. Neurosci. 2009, 42, 75–80, doi:10.1016/j.mcn.2009.06.001.

De Felice, F.G.; Wu, D.; Lambert, M.P.; Fernandez, S.J.; Velasco, P.T.; Lacor, P.N.; Bigio, E.H.; Jerecic, J.; Acton, P.J.; Shughrue, P.J.; et al. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging 2008, 29, 1334–1347, doi:10.1016/j.neurobiolaging.2007.02.029.

Dohler, F.; Sepulveda-Falla, D.; Krassmann, S.; Altmeppen, H.; Schluter, H.; Hildebrand, D.; Zerr, I.; Matschke, J.; Glatzel, M. High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer’s disease. Brain 2014, 137, 873–886, doi:10.1093/brain/awt375.

Gunther, E.C.; Strittmatter, S.M. Beta-amyloid oligomers and cellular prion protein in Alzheimer’s disease. J. Mol. Med. (Berl) 2010, 88, 331–338, doi:10.1007/s00109-009-0568-7.

Caetano, F.A.; Beraldo, F.H.; Hajj, G.N.; Guimaraes, A.L.; Jurgensen, S.; Wasilewska-Sampaio, A.P.; Hirata, P.H.; Souza, I.; Machado, C.F.; Wong, D.Y.; et al. Amyloid-beta oligomers increase the localization of prion protein at the cell surface. J. Neurochem. 2011, 117, 538–553, doi:10.1111/j.1471-4159.2011.07225.x.

Kellett, K.A.; Hooper, N.M. Prion protein and Alzheimer disease. Prion 2009, 3, 190–194, doi:10.4161/prion.3.4.9980.
195. Rushworth, J.V.; Griffiths, H.H.; Watt, N.T.; Hooper, N.M. Prion protein-mediated toxicity of amyloid-beta oligomers requires lipid rafts and the transmembrane LRP1. *J. Biol. Chem.* 2013, 288, 8935–8951, doi:10.1074/jbc.M112.400358.

196. Gimbel, D.A.; Nyaaga, H.B.; Coffey, E.E.; Gunther, E.C.; Lauren, I.; Gimbel, Z.A.; Strittmatter, S.M. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. *J. Neurosci.* 2010, 30, 6367–6374, doi:10.1523/JNEUROSCI.0995-10.2010.

197. You, H.; Tsutsui, S.; Hameed, S.; Kannanaya kal, T.J.; Chen, L.; Xia, P.; Engbers, J.D.; Lipton, S.A.; Stys, P.K.; Zamponi, G.W. Abeta neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. *Proc. Natl. Acad. Sci. USA* 2012, 109, 1737–1742, doi:10.1073/pnas.1110789109.

198. Kudo, W.; Lee, H.P.; Zou, W.Q.; Wang, X.; Perry, G.; Zhu, X.; Smith, M.A.; Petersen, R.B.; Lee, H.G. Cellular prion protein is essential for oligomeric amyloid-beta-induced neuronal cell death. *Hum. Mol. Genet.* 2012, 21, 1138–1144, doi:10.1093/hmg/ddr542.

199. Barry, A.E.; Klyubin, I.; Mc Donald, J.M.; Mably, A.J.; Farrell, M.A.; Scott, M.; Walsh, D.M.; Rowan, M.J. Alzheimer’s disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. *J. Neurosci.* 2011, 31, 7259–7263, doi:10.1523/JNEUROSCI.6500-10.2011.

200. Um, J.W.; Nyaaga, H.B.; Heiss, J.K.; Kostylev, M.A.; Stagi, M.; Vortmeyer, A.; Wisniewski, T.; Gunther, E.C.; Strittmatter, S.M. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. *Nat. Neurosci.* 2012, 15, 1227–1235, doi:10.1038/nn.3178.

201. Um, J.W.; Strittmatter, S.M. Amyloid-beta induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. *Prion* 2013, 7, 37–41, doi:10.4161/prion.22212.

202. Hamilton, A.; Zamponi, G.W.; Ferguson, S.S. Glutamate receptors function as scaffolds for the regulation of beta-amyloid and cellular prion protein signaling complexes. *Mol. Brain* 2015, 8, 18, doi:10.1186/s13041-015-0107-1.

203. Mattei, V.; Garofalo, T.; Misasi, R.; Circeella, A.; Manganelli, V.; Lucania, G.; Pavan, A.; Sorice, M. Prion protein is a component of the multidimensional signaling complex involved in T cell activation. *Fems Lett.* 2004, 560, 14–18, doi:10.1016/S0014-5793(04)00029-8.

204. Caru, N.; Fisesi, I.; Priester, A.; Ciotti, M.T.; Biocca, S. Altered intracellular distribution of PrPC and impairment of proteasome activity in tau overexpressing cortical neurons. *J. Alzheimers Dis.* 2011, 27, 603–613, doi:10.3233/JAD-2011-110446.

205. Haas, L.T.; Kostylev, M.A.; Strittmatter, S.M. Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). *J. Biol. Chem.* 2014, 289, 28460–28477, doi:10.1074/jbc.M114.584342.

206. Vilches, S.; Vergara, C.; Nicolas, O.; Sanclimens, G.; Merino, S.; Varon, S.; Acosta, G.A.; Albericio, F.; Royo, M.; Del Rio, J.A.; et al. Neurotoxicity of prion peptides mimicking the central domain of the cellular prion protein. *PLoS ONE* 2013, 8, e70881, doi:10.1371/journal.pone.0070881.

207. Goniotaki, D.; Lakkaraju, A.K.K.; Shrivastava, A.N.; Bakirci, P.; Sorce, S.; Senatore, A.; Marpakwar, R.; Hornemann, S.; Gasparini, F.; Triller, A.; et al. Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity. *PLoS Pathog.* 2017, 13, e1006733, doi:10.1371/journal.ppat.1006733.

208. Hernandez-Rapp, I.; Martin-Lanneree, S.; Hirsch, T.Z.; Launay, J.M.; Mouillet-Richard, S. Hijacking PrP(c)-dependent signal transduction: When prions impair Abeta clearance. *Front. Aging Neurosci.* 2014, 6, 25, doi:10.3389/fnagi.2014.00025.

209. Larson, M.; Sherman, M.A.; Amar, F.; Nuvolone, M.; Schneider, J.A.; Bennett, D.A.; Aguzzi, A.; Lesne, S.E. The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer’s disease. *J. Neurosci.* 2012, 32, 16857–16871a, doi:10.1523/JNEUROSCI.1858-12.2012.

210. Kessels, H.W.; Nguyen, L.N.; Nabavi, S.; Malinow, R. The prion protein as a receptor for amyloid-beta. *Nature* 2010, 466, E3–E4, discussion E4-5, doi:10.1038/nature09217.

211. Balducci, C.; Beeg, M.; Stravalaci, M.; Bastone, A.; Sclip, A.; Biasini, E.; Tapella, L.; Colombo, L.; Manzoni, C.; Borsello, T.; et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. *Proc. Natl. Acad. Sci. USA* 2010, 107, 2295–2303, doi:10.1073/pnas.0911829107.

212. Calella, A.M.; Farinelli, M.; Nuvolone, M.; Mirante, O.; Moos, R.; Falsig, J.; Mansuy, I.M.; Aguzzi, A. Prion protein and Abeta-related synaptic toxicity impairment. *EMBO Mol. Med.* 2010, 2, 306–314, doi:10.1002/emmm.201000082.
213. Younan, N.D.; Sarell, C.J.; Davies, P.; Brown, D.R.; Viles, J.H. The cellular prion protein traps Alzheimer’s Abeta in an oligomeric form and disassembles amyloid fibers. FASEB J. 2013, 27, 1847–1858, doi:10.1096/fj.12-222588.

214. Pietri, M.; Dakowski, C.; Hannaoui, S.; Alleaume-Butaux, A.; Hernandez-Rapp, J.; Ragagnin, A.; Mouillet-Richard, S.; Haik, S.; Bailly, Y.; Peyrin, J.M.; et al. PDK1 decreases TACE-mediated alpha-secretase activity and promotes disease progression in prion and Alzheimer’s diseases. Nat. Med. 2013, 19, 1124–1131, doi:10.1038/nm.3302.

215. Resenberger, U.K.; Winklhofer, K.F.; Tatjelt, J. Cellular prion protein mediates toxic signaling of amyloid beta. Neurodegener. Dis. 2010, 12, 298–330, doi:10.1159/000332596.

216. Chen, R.J.; Chang, W.W.; Lin, Y.C.; Cheng, P.L.; Chen, Y.R. Alzheimer’s Amyloid-beta Oligomers Rescue Cellular Prion Protein Induced Tau Reduction via Fyn Pathways. ACS Chem. Neurosci. 2013, doi:10.1021/cn400085q.

217. Schmitz, M.; Wulf, K.; Signore, S.C.; Schulz-Schaeffer, W.J.; Kermer, P.; Bahr, M.; Wouters, F.S.; Zafar, S.; Zerr, I. Impact of the cellular prion protein on amyloid-beta and 3PO-tau processing. J. Alzheimers Dis. 2014, 38, 551–565, doi:10.3233/JAD-130566.

218. Ishizawa, K.; Mitsufuji, T.; Shioda, K.; Kobayashi, A.; Komori, T.; Nakazato, Y.; Kitamoto, T.; Araki, N.; Yamamoto, T.; Sasaki, A. An autopsy report of three kindred in a Gerstmann-Straussler-Scheinker disease P105L family with a special reference to prion protein, tau, and beta-amyloid. Brain Behav. 2018, 8, e01117, doi:10.1002/brb3.1117.

219. Matamoros-Angles, A.; Gayosso, L.M.; Richaud-Patin, Y.; di Domenico, A.; Vergara, C.; Hervera, A.; Sousa, A.; Fernandez-Borges, N.; Consiglio, A.; Gavin, R.; et al. iPSC Cell Cultures from a Gerstmann-Straussler-Scheinker Patient with the Y218N PRNP Mutation Recapitulate tau Pathology. Mol. Neurobiol. 2017, doi:10.1007/s12035-017-9506-6.

220. Jansen, C.; Parchi, P.; Capellari, S.; Strammelli, R.; Dopper, E.G.; van Swieten, J.C.; Kamphorst, W.; Rozemuller, A.J. A second case of Gerstmann-Straussler-Scheinker disease linked to the G131V mutation in the prion protein gene in a Dutch patient. J. Neuropathol. Exp. Neurol. 2011, 70, 698–702, doi:10.1097/NEN.0b013e3182270c54.

221. Llorens, F.; Ansoleaga, B.; Garcia-Esparcia, P.; Zafar, S.; Grau-Rivera, O.; Lopez-Gonzalez, I.; Blanco, R.; Carmona, M.; Yague, J.; Nos, C.; et al. PrP mRNA and protein expression in brain and PrP in CSF in Creutzfeldt-Jakob disease MM1 and VV2. Prion 2013, 7, doi:10.4161/prion.26416.

222. Bradley, C.A.; Peineau, S.; Taghibiglou, C.; Nicolas, C.S.; Whitcomb, D.J.; Bortolotto, Z.A.; Kaang, B.K.; Cho, K.; Wang, Y.T.; Collingridge, G.L. A pivotal role of GSK-3 in synaptic plasticity. Front. Mol. Neurosci. 2012, 5, 13, doi:10.3389/fnmol.2012.00013.

223. Guglielmiuto, M.; Giliberto, L.; Tamagnone, E.; Tabaton, M. Oxidative stress mediates the pathogenic effect of different Alzheimer’s disease risk factors. Front. Aging Neurosci. 2010, 2, 3, doi:10.3389/neuro.24.003.2010.

224. Wadsworth, J.D.; Hill, A.F.; Beck, J.A.; Collinge, J. Molecular and clinical classification of human prion disease. Br. Med. Bull. 2003, 66, 241–254, doi:10.1093/bmb/66.1.241.

225. McNeill, A. A molecular analysis of prion protein expression in Alzheimer’s disease. Mcgill J. Med. 2004, 8, 7–14.

226. Rezaie, P.; Pontikis, C.C.; Hudson, L.; Cairns, N.J.; Lantos, P.L. Expression of cellular prion protein in the frontal and occipital lobe in Alzheimer’s disease, diffuse Lewy body disease, and in normal brain: An immunohistochemical study. J. Histochem. Cytochem. 2005, 53, 929–940, doi:10.1369/jhc.4A6551.2005.

227. Watt, N.T.; Taylor, D.R.; Kerrigan, T.L.; Griffiths, H.H.; Rushworth, J.V.; Whitehouse, I.J.; Hooper, N.M. Prion protein facilitates uptake of zinc into neuronal cells. Nat. Commun. 2012, 3, 1134, doi:10.1038/ncomms2135.

228. Lee, J.Y.; Cole, T.B.; Palmiter, R.D.; Suh, S.W.; Koh, J.Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99, 7705–7710, doi:10.1073/pnas.092034699.

229. Bush, A.L.; Pettingell, W.H.; Multhaup, G.; d Paradis, M.; Vonsattel, J.P.; Gusella, J.F.; Beyreuther, K.; Masters, C.L.; Tanzi, R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994, 265, 1464–1467.

230. Deshpande, A.; Kawai, H.; Metherate, R.; Glabe, C.G.; Busciglio, J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J. Neurosci. 2009, 29, 4004–4015, doi:10.1523/JNEUROSCI.5980-08.2009.
231. Whitehouse, I.J.; Miners, J.S.; Glennon, E.B.; Kehoe, P.G.; Love, S.; Kellett, K.A.; Hooper, N.M. Prion protein is decreased in Alzheimer’s brain and inversely correlates with BACE1 activity, amyloid-beta levels and Braak stage. *PloS ONE* 2013, 8, e59554, doi:10.1371/journal.pone.0059554.

232. Beyer, N.; Coulson, D.T.; Heggarty, S.; Ravid, R.; Hellemans, J.; Irvine, G.B.; Johnston, J.A. Zinc transporter mRNA levels in Alzheimer’s disease postmortem brain. *J. Alzheimers Dis.* 2012, 29, 863–873, doi:10.3233/JAD-2012-112105.

233. Li, S.H.; Li, X.J. Huntingtin-protein interactions and the pathogenesis of Huntington’s disease. *Trends Genet.* 2004, 20, 146–154, doi:10.1016/j.tig.2004.01.008.

234. Landles, C.; Bates, G.P. Huntington and the molecular pathogenesis of Huntington’s disease. Fourth in molecular medicine review series. *EMBO Rep.* 2004, 5, 958–963, doi:10.1038/sj.embor.7400250.

235. Saudou, F.; Humbert, S. The Biology of Huntingtin. *Neuron* 2016, 89, 910–926, doi:10.1016/j.neuron.2016.02.003.

236. de la Monte, S.M.; Vonsattel, J.P.; Richardson, E.P., Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington’s disease. *J. Neuropathol. Exp. Neurol.* 1988, 47, 516–525.

237. Vonsattel, J.P.; DiFiglia, M. Huntington disease. *J. Neuropathol. Exp. Neurol.* 1998, 57, 369–384.

238. Strong, T.V.; Tagle, D.A.; Valdes, J.M.; Elmer, L.W.; Boehm, K.; Swaroop, M.; Kaatz, K.W.; Collins, F.S.; Albin, R.L. Widespread expression of the human and rat Huntingdon’s disease gene in brain and nonneural tissues. *Nat. Genet.* 1993, 5, 259–265, doi:10.1038/ng1193-259.

239. Lee, F.J.; Liu, F. Genetic factors involved in the pathogenesis of Parkinson’s disease. *Brain Res. Rev.* 2008, 58, 354–364, doi:10.1016/j.brainresrev.2008.02.001.

240. Bartels, A.L.; Leenders, K.L. Parkinson’s disease: The syndrome, the pathogenesis and pathophysiology. *Cortex* 2009, 45, 915–921, doi:10.1016/j.cortex.2008.11.010.

241. Goedert, M.; Spillantini, M.G.; Del Tredici, K.; Braak, H. 100 years of Lewy pathology. *Nat. Rev. Neurol.* 2013, 9, 13–24, doi:10.1038/nnrneurol.2012.242.

242. Butterfield, D.A.; Perluigi, M.; Sultana, R. Oxidative stress in Alzheimer’s disease brain: New insights from redox proteomics. *Eur. J. Pharm.* 2006, 545, 39–50, doi:10.1016/j.ejpb.2006.06.026.

243. Toulorge, D.; Schapira, A.H.; Hajj, R. Molecular changes in the postmortem parkinsonian brain. *J. Neurochem.* 2016, 10.1111/jnc.13696, doi:10.1111/jnc.13696.

244. Ribeiro, F.M.; Vieira, L.B.; Pires, R.G.; Olmo, R.P.; Fergusson, S.S. Metabotropic glutamate receptors and neurodegenerative diseases. *Pharm. Res.* 2017, 115, 179–191, doi:10.1007/j.phrs.2016.11.013.

245. Lewerenz, J.; Maher, P. Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence? *Front. Neurosci.* 2015, 9, 469, doi:10.3389/fnins.2015.00469.

246. Choi, D.W. Glutamate neurotoxicity and diseases of the nervous system. *Neuron* 1988, 1, 623–634, doi:0896-6273(88)90162-6.

247. Balazs, R.; Miller, S.; Romano, C.; de Vries, A.; Chun, Y.; Cotman, C.W. Metabotropic glutamate receptor mGluR5 in astrocytes: Pharmacological properties and agonist regulation. *J. Neurochem.* 1997, 69, 151–163.

248. Amalric, M. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson’s disease. *Curr. Opin. Pharm.* 2015, 20, 29–34, doi:10.1016/j.coph.2014.11.001.

249. Breyssse, N.; Baunez, C.; Spooren, W.; Gasparini, F.; Amalric, M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the a kinetin defects in a rat model of parkinsonism. *J. Neurosci.* 2002, 22, 5669–5678, doi:10.1523/JNEUROSCI.22-13-05669.2002.

250. Coccurello, R.; Breyssse, N.; Amalric, M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. *Neuropsychopharmacology* 2004, 29, 1451–1461, doi:10.1038/sj.npp.1300444.

251. Phillips, J.M.; Lam, H.A.; Ackerson, L.C.; Maidment, N.T. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson’s disease. *Eur. J. Neurosci.* 2006, 23, 151–160, doi:10.1111/j.1460-9586.2005.04550.x.

252. Ossowska, K.; Konieczny, J.; Wardas, J.; Pietraszek, M.; Kuter, K.; Wolfarth, S.; Pilc, A. An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. *Amino Acids* 2007, 32, 179–188, doi:10.1007/s00726-006-0317-y.

253. Thakur, A.K.; Jayaraman, M.; Mishra, R.; Thakur, M.; Chellgren, V.M.; Byeon, I.J.; Anjum, D.H.; Kodali, R.; Creamer, T.P.; Conway, J.F.; et al. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. *Nat. Struct. Mol. Biol.* 2009, 16, 380–389, doi:10.1038/nsmb.1570.
254. Fernandez-Nogales, M.; Cabrera, J.R.; Santos-Galindo, M.; Hoozemans, J.J.; Ferrer, I.; Rozemuller, A.J.; Hernandez, F.; Avila, J.; Lucas, J.J. Huntington's disease is a four-repeat tauopathy with tau nuclear rods. *Nat. Med.* **2014**, *20*, 881–885, doi:10.1038/nm.3617.

255. Carmichael, J.; Sugars, K.L.; Bao, Y.P.; Rubinsztein, D.C. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington’s disease mutation. *J. Biol. Chem.* **2002**, *277*, 33791–33798, doi:10.1074/jbc.M204861200.

256. Surgucheva, I.; Sharov, V.S.; Surguchov, A. gamma-Synuclein: Seeding of alpha-synuclein aggregation and transmission between cells. *Biochemistry* **2012**, *51*, 4743–4754, doi:10.1021/bi300478w.

257. Urrea, L.; Ferrer, I.; Gavin, R.; Del Rio, J.A. The cellular prion protein (PrPC) as neuronal receptor for alpha-synuclein. *Prion* **2017**, *11*, 226–233, doi:10.1080/19336896.2017.1334748.

258. Mao, X.; Ou, M.T.; Karuppagounder, S.S.; Kam, T.I.; Yin, X.; Xiong, Y.; Ge, P.; Umanah, G.E.; Brahmachari, S.; Shin, J.H.; et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. *Science* **2016**, *353*, doi:10.1126/science.aah3374.

259. De Cecco, E.; Legname, G. The role of the prion protein in the internalization of alpha-synuclein amyloids. *Prion* **2018**, *12*, 23–27, doi:10.1080/19336896.2017.1423186.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).